<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="biof2122" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Biofactors</journal-id><journal-id journal-id-type="iso-abbrev">Biofactors</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)1872-8081</journal-id><journal-id journal-id-type="publisher-id">BIOF</journal-id><journal-title-group><journal-title>Biofactors (Oxford, England)</journal-title></journal-title-group><issn pub-type="ppub">0951-6433</issn><issn pub-type="epub">1872-8081</issn><publisher><publisher-name>John Wiley &#x00026; Sons, Inc.</publisher-name><publisher-loc>Hoboken, USA</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39275884</article-id><article-id pub-id-type="pmc">PMC11681214</article-id>
<article-id pub-id-type="doi">10.1002/biof.2122</article-id><article-id pub-id-type="publisher-id">BIOF2122</article-id><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Cannabinol modulates the endocannabinoid system and shows <styled-content style="fixed-case" toggle="no">TRPV1</styled-content>&#x02010;mediated anti&#x02010;inflammatory properties in human keratinocytes</article-title><alt-title alt-title-type="left-running-head">Di Meo et al.</alt-title></title-group><contrib-group><contrib id="biof2122-cr-0001" contrib-type="author"><name><surname>Di Meo</surname><given-names>Camilla</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2045-3114</contrib-id><xref rid="biof2122-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="biof2122-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="biof2122-cr-0002" contrib-type="author"><name><surname>Tortolani</surname><given-names>Daniel</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6704-9023</contrib-id><xref rid="biof2122-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="biof2122-cr-0003" contrib-type="author"><name><surname>Standoli</surname><given-names>Sara</given-names></name><xref rid="biof2122-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="biof2122-cr-0004" contrib-type="author"><name><surname>Ciaramellano</surname><given-names>Francesca</given-names></name><xref rid="biof2122-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="biof2122-cr-0005" contrib-type="author"><name><surname>Angelucci</surname><given-names>Beatrice Clotilde</given-names></name><xref rid="biof2122-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="biof2122-cr-0006" contrib-type="author"><name><surname>Tisi</surname><given-names>Annamaria</given-names></name><xref rid="biof2122-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="biof2122-cr-0007" contrib-type="author"><name><surname>Kadhim</surname><given-names>Salam</given-names></name><xref rid="biof2122-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="biof2122-cr-0008" contrib-type="author"><name><surname>Hsu</surname><given-names>Eric</given-names></name><xref rid="biof2122-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="biof2122-cr-0009" contrib-type="author" corresp="yes"><name><surname>Rapino</surname><given-names>Cinzia</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9759-2449</contrib-id><xref rid="biof2122-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>crapino@unite.it</email></address></contrib><contrib id="biof2122-cr-0010" contrib-type="author" corresp="yes"><name><surname>Maccarrone</surname><given-names>Mauro</given-names></name><xref rid="biof2122-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="biof2122-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><address><email>mauro.maccarrone@univaq.it</email></address></contrib></contrib-group><aff id="biof2122-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Veterinary Medicine</named-content>
<institution>University of Teramo</institution>
<city>Teramo</city>
<country country="IT">Italy</country>
</aff><aff id="biof2122-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Biotechnological and Applied Clinical Sciences</named-content>
<institution>University of L'Aquila</institution>
<city>L'Aquila</city>
<country country="IT">Italy</country>
</aff><aff id="biof2122-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">European Center for Brain Research (CERC)</named-content>
<institution>Santa Lucia Foundation IRCCS</institution>
<city>Rome</city>
<country country="IT">Italy</country>
</aff><aff id="biof2122-aff-0004">
<label>
<sup>4</sup>
</label>
<institution>InMed Pharmaceuticals Inc.</institution>
<city>Vancouver</city>
<named-content content-type="country-part">BC</named-content>
<country country="CA">Canada</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break/>
Cinzia Rapino, Department of Veterinary Medicine, University of Teramo, 64100 Teramo, Italy.<break/>
Email: <email>crapino@unite.it</email>
<break/>
Mauro Maccarrone, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100 L'Aquila, Italy.<break/>
Email: <email>mauro.maccarrone@univaq.it</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>14</day><month>9</month><year>2024</year></pub-date><pub-date pub-type="ppub"><season>Jan-Feb</season><year>2025</year></pub-date><volume>51</volume><issue seq="240">1</issue><issue-id pub-id-type="doi">10.1002/biof.v51.1</issue-id><elocation-id>e2122</elocation-id><history>
<date date-type="received"><day>03</day><month>6</month><year>2024</year></date>
<date date-type="accepted"><day>27</day><month>8</month><year>2024</year></date>
</history><permissions><!--&#x000a9; 2025 International Union of Biochemistry and Molecular Biology--><copyright-statement content-type="article-copyright">&#x000a9; 2024 The Author(s). <italic toggle="yes">BioFactors</italic> published by Wiley Periodicals LLC on behalf of International Union of Biochemistry and Molecular Biology.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:BIOF-51-0.pdf"/><abstract><title>Abstract</title><p>Cannabinol (CBN) is a secondary metabolite of cannabis whose beneficial activity on inflammatory diseases of human skin has attracted increasing attention. Here, we sought to investigate the possible modulation by CBN of the major elements of the endocannabinoid system (ECS), in both normal and lipopolysaccharide&#x02010;inflamed human keratinocytes (HaCaT cells). CBN was found to increase the expression of cannabinoid receptor 1 (CB<sub>1</sub>) at gene level and that of vanilloid receptor 1 (TRPV1) at protein level, as well as their functional activity. In addition, CBN modulated the metabolism of anandamide (AEA) and 2&#x02010;arachidonoylglicerol (2&#x02010;AG), by increasing the activities of <italic toggle="no">N</italic>&#x02010;acyl phosphatidylethanolamines&#x02010;specific phospholipase D (NAPE&#x02010;PLD) and fatty acid amide hydrolase (FAAH)&#x02014;the biosynthetic and degradative enzyme of AEA&#x02014;and that of monoacylglycerol lipase (MAGL), the hydrolytic enzyme of 2&#x02010;AG. CBN also affected keratinocyte inflammation by reducing the release of pro&#x02010;inflammatory interleukin (IL)&#x02010;8, IL&#x02010;12, and IL&#x02010;31 and increasing the release of anti&#x02010;inflammatory IL&#x02010;10. Of note, the release of IL&#x02010;31 was mediated by TRPV1. Finally, the mitogen&#x02010;activated protein kinases (MAPK) signaling pathway was investigated in inflamed keratinocytes, demonstrating a specific modulation of glycogen synthase kinase 3&#x003b2; (GSK3&#x003b2;) upon treatment with CBN, in the presence or not of distinct ECS&#x02010;directed drugs. Overall, these results demonstrate that CBN modulates distinct ECS elements and exerts anti&#x02010;inflammatory effects&#x02014;remarkably via TRPV1&#x02014;in human keratinocytes, thus holding potential for both therapeutic and cosmetic purposes.</p></abstract><abstract abstract-type="graphical"><p>The figure summarizes the ability of cannabinol to differently modulate gene/protein expression and functionality of endocannabinoid system (ECS) elements in the in vitro model of human keratinocytes (HaCaT cells). Cannabinol is also shown to exert anti&#x02010;inflammatory effects on the release of IL&#x02010;8, IL&#x02010;12, and IL&#x02010;31 (via TRPV1 receptor), as well as of IL&#x02010;10.<boxed-text position="anchor" content-type="graphic" id="biof2122-blkfxd-0001"><graphic xlink:href="BIOF-51-0-g002.jpg" position="anchor" id="jats-graphic-1"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="biof2122-kwd-0001">cannabinol</kwd><kwd id="biof2122-kwd-0002">cytokines</kwd><kwd id="biof2122-kwd-0003">endocannabinoid system</kwd><kwd id="biof2122-kwd-0004">keratinocytes</kwd><kwd id="biof2122-kwd-0005">skin inflammation</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>InMed Pharmaceuticals</funding-source><award-id>PCI0029</award-id></award-group></funding-group><counts><fig-count count="8"/><table-count count="0"/><page-count count="16"/><word-count count="10700"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January/February 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.1 mode:remove_FC converted:28.12.2024</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="biof2122-cit-9001">
<string-name>
<surname>Di Meo</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Tortolani</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Standoli</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ciaramellano</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Angelucci</surname>
<given-names>BC</given-names>
</string-name>, <string-name>
<surname>Tisi</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Cannabinol modulates the endocannabinoid system and shows <styled-content style="fixed-case" toggle="no">TRPV1</styled-content>&#x02010;mediated anti&#x02010;inflammatory properties in human keratinocytes</article-title>. <source>BioFactors</source>. <year>2025</year>;<volume>51</volume>(<issue>1</issue>):<elocation-id>e2122</elocation-id>. <pub-id pub-id-type="doi">10.1002/biof.2122</pub-id>
</mixed-citation>
</p><fn-group id="biof2122-ntgp-0001"><fn id="biof2122-note-0001" fn-type="equal"><p>Camilla Di Meo and Daniel Tortolani contributed equally to this work.</p></fn></fn-group></notes></front><body id="biof2122-body-0001"><sec id="biof2122-sec-0001"><label>1</label><title>INTRODUCTION</title><p>Phytocannabinoids (pCBs) are a group of more than 150 different lipophilic compounds derived from cannabis (<italic toggle="yes">Cannabis sativa</italic>), a flowering plant native to Central Asia.<xref rid="biof2122-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="biof2122-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> Cannabis has been cultivated for millennia with different aims such as nutrition, recreation, generation of seed oil and fibers for industrial purposes, as well as for religious and spiritual practices and, most interestingly, for medical applications.<xref rid="biof2122-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> The best studied pCBs are &#x00394;<sup>9</sup>&#x02010;tetrahydrocannabinol (THC) and cannabidiol (CBD),<xref rid="biof2122-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="biof2122-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> although cannabis produces many other &#x0201c;minor&#x0201d; pCBs whose biological profile remains poorly investigated.<xref rid="biof2122-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="biof2122-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> Recently, improved extraction and (bio)synthetic techniques have led to amounts of less abundant pCBs that are enough to investigate their biological activity.<xref rid="biof2122-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> Among them, cannabinol (CBN) has recently attracted particular attention,<xref rid="biof2122-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="biof2122-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> as a non&#x02010;psychoactive compound whose levels in cannabis flowers increase over time via the first conversion of THC acid (THCA) into THC, and the subsequent oxidation of THC into CBN.<xref rid="biof2122-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="biof2122-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> Recent studies have suggested that CBN may have anti&#x02010;inflammatory, analgesic and antibacterial properties,<xref rid="biof2122-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="biof2122-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="biof2122-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> although the mechanisms of action have still to be clarified.</p><p>In general, pCBs can interact with the endocannabinoid system (ECS),<xref rid="biof2122-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="biof2122-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="biof2122-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> a complex network composed of endocannabinoids (eCBs), their receptors, metabolic enzymes and transporters, which altogether regulate various physiological processes and maintain homeostasis in the human body,<xref rid="biof2122-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="biof2122-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> skin included.<xref rid="biof2122-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="biof2122-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> Anandamide (<italic toggle="yes">N</italic>&#x02010;arachidonoylethanolamine, AEA) and 2&#x02010;arachidonoylglycerol (2&#x02010;AG) are the best studied eCBs, that are both synthesized from membrane phospholipid precursors via different biosynthetic pathways.<xref rid="biof2122-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="biof2122-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="biof2122-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="biof2122-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="biof2122-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="biof2122-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> In particular, the cleavage of <italic toggle="yes">N</italic>&#x02010;arachidonoyl phosphatidylethanolamine (NArPE) by <italic toggle="yes">N</italic>&#x02010;acyl phosphatidylethanolamines&#x02010;specific phospholipase D (NAPE&#x02010;PLD) produces AEA,<xref rid="biof2122-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="biof2122-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> that is hydrolyzed by fatty acid amide hydrolase (FAAH).<xref rid="biof2122-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> 2&#x02010;AG is generated from the cleavage of diacylglycerol (DAG) by the two isoforms of diacylglycerol lipase (DAGL) &#x003b1; and &#x003b2;,<xref rid="biof2122-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> which exhibit distinct spatial and cellular distributions. DAGL&#x003b1; is predominantly localized in the brain,<xref rid="biof2122-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="biof2122-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> while DAGL&#x003b2; is primarily expressed in immune cells including microglia, macrophages, and dendritic cells, being also involved in inflammatory processes.<xref rid="biof2122-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="biof2122-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>, <xref rid="biof2122-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> Then, 2&#x02010;AG is cleaved by monoacylglycerol lipase (MAGL).<xref rid="biof2122-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="biof2122-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> The two main receptors responsible for the biological activity of eCBs are the cannabinoid receptors 1 (CB<sub>1</sub>) and 2 (CB<sub>2</sub>), though other orphan G&#x02010;coupled receptors like the G protein&#x02010;coupled receptor 55 (GPR55), the transient receptor potential (TRP) vanilloid receptor 1 (TRPV1), and peroxisome proliferator&#x02010;activated nuclear receptors (PPARs) &#x003b1;, &#x003b3;, &#x003b4; can be activated by eCBs.<xref rid="biof2122-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> Remarkably, the main components of the ECS have been found in human keratinocytes, which are the predominant cells of the epidermis.<xref rid="biof2122-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="biof2122-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>, <xref rid="biof2122-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>, <xref rid="biof2122-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>, <xref rid="biof2122-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> ECS activation in keratinocytes has been shown to impact on various processes engaged in the regulation of skin physiology, while the dysregulation of the same system is linked to different skin diseases.<xref rid="biof2122-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="biof2122-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="biof2122-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> In this context, we have recently shown that minor pCBs [i.e., cannabigerol (CBG), cannabichromene (CBC), &#x00394;<sup>9</sup>&#x02010;tetrahydrocannabivarin (THCV) and cannabigerolic acid (CBGA)] modulate the expression and functional activity of distinct ECS elements in HaCaT cells,<xref rid="biof2122-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> and block skin inflammation.<xref rid="biof2122-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> Here, we sought to extend these observations to CBN, by using lipopolysaccharide (LPS)&#x02010;inflamed HaCaT cells. Taken together, our data reveal different CBN&#x02010;induced modulations of the ECS, as well as its anti&#x02010;inflammatory effect by reducing IL&#x02010;31 release through a TRPV1&#x02010;dependent mechanism.</p></sec><sec sec-type="materials-and-methods" id="biof2122-sec-0002"><label>2</label><title>MATERIALS AND METHODS</title><sec sec-type="materials" id="biof2122-sec-0003"><label>2.1</label><title>Materials</title><p>Dulbecco's modified Eagle medium&#x02010;high glucose (DMEM&#x02010;HG) and fetal bovine serum (FBS) were purchased from Corning Incorporated (NY, USA); antibiotics (penicillin/streptomycin, pen/strep), Dulbecco's phosphate buffer saline (D&#x02010;PBS without calcium and magnesium), and trypsin (2.5%) were from Gibco by Life Technologies (Thermo Fisher Scientific Company, Waltham, MA, USA); ethylenediamine tetraacetic acid (EDTA, 0.5&#x02009;M) was from Invitrogen (Thermo Fisher Scientific Company, Waltham, MA, USA); Opti&#x02010;MEM was from Thermo Fisher Scientific (Waltham, MA, USA). CBN was purchased from Cerilliant Corporation (Sigma Aldrich Company, St. Louis, MO, USA). LPS from <italic toggle="yes">Escherichia coli</italic> O111:B4 (suitable for cell culture) and hydrocortisone (HC) were purchased from Sigma Aldrich (St. Louis, MO, USA). The agonist capsaicin, the antagonists SR141716A and CPZ were obtained from Sigma Aldrich (St. Louis, MO, USA). 3&#x02010;(4,5&#x02010;Dimethylthiazol&#x02010;2&#x02010;yl)&#x02010;2,5&#x02010;diphenyltetrazolium bromide (MTT) reagent was purchased from Sigma&#x02010;Aldrich (St. Louis, MO, USA) and dimethyl sulfoxide (DMSO) was from PanReac AppliChem (Glenview, IL, USA). ELISA kit to detect apoptosis was purchased from Roche Diagnostic (Basilea, Switzerland), while ELISA selective kits for each interleukin were purchased from R&#x00026;D System DuoSet (Bio&#x02010;Techne, Minneapolis, MN, USA). Supplies for the RT&#x02010;qPCR, including the RevertAid H Minus First Strand cDNA Synthesis Kit and SensiFAST SYBR Lo&#x02010;ROX Kit, were obtained from Thermo Fisher Scientific (Waltham, MA, USA) and Bioline (Meridian Bioscience Inc. Company, Cincinnati, OH, USA), respectively, whereas supplies for Western blotting were purchased from Bio&#x02010;Rad Laboratories (Hercules, California, USA). [3H]CP55.940, CP55.940, and [3H]AEA were from PerkinElmer Life Sciences (Waltham, MA, USA); Fluo&#x02010;3 AM and Pluronic F&#x02010;127 were from Molecular Probes (Thermo Fisher Scientific, Waltham, MA, USA); N&#x02010;((6&#x02010;(2,4 dinitrophenyl)amino)hexanoyl)&#x02010;2(4,4&#x02010;difluoro&#x02010;5,7&#x02010;dimethyl&#x02010;4&#x02010;bora&#x02010;3a,4a&#x02010;diaza&#x02010;s indacene&#x02010;3&#x02010;pentanoyl)&#x02010;1&#x02010;hexadecanoyl&#x02010;sn&#x02010;glycero&#x02010;3 phosphoethanolamine, triethylammonium salt (PED6) was from Thermo Fisher Scientific (Waltham, MA, USA); p&#x02010;nitrophenyl butyrate (pNPB) was from Sigma Aldrich (St. Louis, MO, USA) and KT172 and arachidonoyl&#x02010;1&#x02010;thio&#x02010;glycerol were from Cayman Chemical (Ann Arbor, MI, USA). Human/mouse MAPK phosphorylation array was obtained from RayBiotech (RayBiotech Inc., Peachtree Corners, GA, USA).</p></sec><sec id="biof2122-sec-0004"><label>2.2</label><title>Cell line and treatments</title><p>Immortalized HaCaT cells of Caucasian skin type (phototype) from the original depositor (DKFZ, Heidelberg) were purchased from Cell Lines Service (CLS Cell Lines Service, 300493). In all the experiments, HaCaT cells were used at the 5th&#x02013;6th passage after thawing, cultured at 37&#x000b0;C in a humidified 5% CO<sub>2</sub> atmosphere in DMEM&#x02010;HG and supplemented with 10% FBS and 1% antibiotic&#x02013;antimycotic (pen/strep) solution. For MTT and apoptosis assays, RT&#x02010;qPCR, western blotting, receptors binding, and enzymes activity assays, cells were seeded in specific plates and, after 24&#x02009;h, the cell medium was replaced with DMEM&#x02010;HG supplemented with 1% FBS and 1% pen/strep (starvation medium) and incubated for 6, 12, 24, and/or 48&#x02009;h in the presence of CBN at specific concentrations (&#x003bc;M) according to each analysis. For the ELISA assay and MAPK array, performed in inflammatory conditions, cells were starved with DMEM&#x02010;HG with 1% FBS and 1% pen/strep for 24&#x02009;h and then incubated as the following conditions: control (DMEM&#x02010;HG&#x02009;+&#x02009;5% FBS&#x02009;+&#x02009;1% pen/strep); LPS at the concentration of 5.0&#x02009;&#x003bc;g/mL, positive control HC at 10&#x02009;&#x003bc;M; CBN at 2.5&#x02009;&#x003bc;M alone and in combination with the selective CB<sub>1</sub> antagonist (SR141716A) at 0.1&#x02009;&#x003bc;M<xref rid="biof2122-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref> and the selective TRPV1 antagonist CPZ at 5.0&#x02009;&#x003bc;M.<xref rid="biof2122-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref> After 24 and 48&#x02009;h, according to specific analysis, cell pellets and supernatants (medium) were collected from each condition, and then centrifuged at 300<italic toggle="yes">g</italic> for 5&#x02009;min and stored at &#x02212;20 and at &#x02212;80&#x000b0;C, respectively.</p></sec><sec id="biof2122-sec-0005"><label>2.3</label><title>
<styled-content style="fixed-case" toggle="no">MTT</styled-content> cytotoxicity assay</title><p>HaCaT cells were seeded into 96&#x02010;well plates at a density of 1&#x02009;&#x000d7;&#x02009;10<sup>4</sup> per well and the day after were treated with vehicle (0.8% methanol) and CBN at different concentrations (0.5, 1.0, 2.5, 5.0, 10, and 25&#x02009;&#x003bc;M), for the timepoints of 6, 12, and 24&#x02009;h. After each timepoint, cells were incubated with MTT reagent at the final concentration of 0.5&#x02009;mg/mL for 4&#x02009;h. Then, the MTT solution was discarded, and DMSO was added to dissolve the formazan crystals. Cell viability was assessed by the reduction of the MTT reagent to purple formazan, by measuring the optical densities (OD) values at the EnSpire Multimode Plate Reader (Perkin Elmer, Waltham, MA, USA). Cell viability was expressed as percentage of control (100%), calculated by subtracting the 630&#x02009;nm OD background from the 570&#x02009;nm OD total signal for each sample, followed by the subtraction of cell&#x02010;free blank wells, as reported.<xref rid="biof2122-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref>
</p></sec><sec id="biof2122-sec-0006"><label>2.4</label><title>Determination of apoptosis</title><p>HaCaT cells were seeded into 96&#x02010;well plates at a density of 1&#x02009;&#x000d7;&#x02009;10<sup>4</sup> per well and the day after were treated with CBN at different concentrations (0.5, 1.0, 2.5, 5.0, 10, and 25&#x02009;&#x003bc;M) for 24&#x02009;h. Apoptotic cell death was quantified by an ELISA assay (Cell Death Detection ELISAPLUS, #11774425001, Roche Diagnostic, Basilea, Switzerland), based on the evaluation of DNA fragmentation through an immunoassay for histone&#x02010;associated DNA fragments in the cell cytoplasm. The ELISA kit also provides a positive control, represented by a DNA&#x02013;histone&#x02010;complex. Specific determination of mono&#x02010; and oligonucleosomes in the cytoplasmic fraction of cell lysates was performed by measuring the absorbance values at 405&#x02009;nm, as reported.<xref rid="biof2122-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref>
</p></sec><sec id="biof2122-sec-0007"><label>2.5</label><title>Quantitative real&#x02010;time polymerase chain reaction</title><p>HaCaT cells were seeded into six&#x02010;well plates at a density of 4&#x02009;&#x000d7;&#x02009;10<sup>5</sup> per well, incubated overnight, and then exposed to CBN at 2.5&#x02009;&#x003bc;M for 24&#x02009;h. After treatments, cell pellets were collected and stored at &#x02212;20&#x000b0;C. Total RNA was extracted from the cell pellets by using QIAzol Lysis Reagent (Qiagen, Hilden, Germany), according to manufacturer's instructions, and then quantified with a NanoDrop&#x02122; 2000/2000c Spectrophotometer (Thermo Fisher Scientific Company, Waltham, MA, USA). Five hundred nanograms of isolated mRNA was reverse transcribed in a final volume of 20&#x02009;&#x003bc;L, later diluted 1:3, following incubation in a thermocycler for 5&#x02009;min at 65&#x000b0;C, 5&#x02009;min at 25&#x000b0;C, 60&#x02009;min at 42&#x000b0;C, and 5&#x02009;min at 70&#x000b0;C, by using the RevertAid H Minus First Strand cDNA Synthesis (Thermo Fisher Scientific Company, Waltham, MA, USA). Quantitative real&#x02010;time polymerase chain reaction (RT&#x02010;qPCR) was performed in a final volume of 10&#x02009;&#x003bc;L, consisting of 1&#x02009;&#x003bc;L of cDNA, 1&#x02009;&#x003bc;L of primers Forward&#x02009;+&#x02009;Reverse (10&#x02009;&#x003bc;M mix) and 5&#x02009;&#x003bc;L of Sybr Green 1&#x000d7; (SensiFAST SYBR Lo&#x02010;ROX Kit, Bioline by Meridian Bioscience Inc., Cincinnati, OH, USA), in the Applied Biosystems 7500 Fast Real&#x02010;Time PCR System (Life Technologies, Carlsbad, CA, USA). The qPCR reaction was performed with the following conditions: holding at 50&#x000b0;C for 2&#x02009;min and 95&#x000b0;C for 10&#x02009;min, cycling at 95&#x000b0;C for 15&#x02009;s and 60&#x000b0;C for 30&#x02009;s (for 40 cycles) and a dissociation curve (melting curve) in the range of 60&#x02013;95&#x000b0;C,<xref rid="biof2122-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> to evaluate the specificity of the amplification products. After assigning a fluorescence threshold above background (threshold cycle number or <italic toggle="yes">C</italic>
<sub>t</sub>), differences in threshold cycle number were used to quantify the relative amount of each PCR target. The relative expression of different amplicons was calculated by the delta&#x02013;delta <italic toggle="yes">C</italic>
<sub>t</sub> (&#x00394;&#x00394;<italic toggle="yes">C</italic>
<sub>t</sub>) method and was converted to relative expression ratio (2&#x02212;<sup>&#x00394;&#x00394;<italic toggle="yes">C</italic>t</sup>) for statistical analysis.<xref rid="biof2122-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref> All data were normalized to the endogenous reference genes &#x003b2;&#x02010;actin and glyceraldehyde&#x02010;3&#x02010;phosphate dehydrogenase (GAPDH). The specific primers used were designed with Primer3 and ordered from Integrated DNA Technologies (IDT; Coralville, IA, USA), and their specific sequences are indicated in Table&#x000a0;<xref rid="biof2122-supitem-0001" ref-type="supplementary-material">S2</xref>.</p></sec><sec id="biof2122-sec-0008"><label>2.6</label><title>Western blotting</title><p>HaCaT cells were seeded into six&#x02010;well plates at a density of 4&#x02009;&#x000d7;&#x02009;10<sup>5</sup> per well, incubated overnight, and then treated with CBN at 2.5&#x02009;&#x003bc;M for 24&#x02009;h. Cell pellets were collected and then lyzed in ice&#x02010;cold RIPA lysis buffer (Thermo Fisher Scientific Company, Waltham, MA, USA) in combination with the protease inhibitor cocktail 100&#x000d7; (Sigma Aldrich, St. Louis, MO, USA). The amount of protein was determined by the Bio&#x02010;Rad Protein assay (Bio&#x02010;Rad Laboratories, Hemel Hempstead, UK). An equal amount of protein (60&#x02009;&#x003bc;g) for each sample was loaded onto 10% sodium dodecyl sulfate (SDS)&#x02013;polyacrylamide gels and blotted onto polyvinylidene fluoride (PVDF) sheets (Amersham Biosciences, Piscataway, NJ, USA). Membranes were blocked with 5% non&#x02010;fat dried milk for 1&#x02009;h at room temperature, and then incubated with suitable primary antibodies. Detection was performed using Azure Biosystems c400 (Dublin, CA, USA). The primary antibodies used were obtained from various sources, as detailed in Table&#x000a0;<xref rid="biof2122-supitem-0001" ref-type="supplementary-material">S3</xref>.</p></sec><sec id="biof2122-sec-0009"><label>2.7</label><title>
<styled-content style="fixed-case" toggle="no">CB<sub>1</sub>
</styled-content> binding assay</title><p>HaCaT cells were seeded in 12&#x02010;well plates at a density of 2&#x02009;&#x000d7;&#x02009;10<sup>5</sup> cells per well under the following conditions, each in triplicate: total binding (TB), non&#x02010;specific binding (NSB), CB<sub>1</sub> receptor antagonist (SR141716), and blanks (Bk). Cells were then treated with 2.5&#x02009;&#x003bc;M CBN for 24&#x02009;h. After two washes with 1&#x02009;mL PBS, each well was incubated with 500&#x02009;&#x003bc;L of incubation buffer (50&#x02009;mM Tris&#x02013;HCl, 5&#x02009;mM MgCl<sub>2</sub>, 1&#x02009;mM CaCl<sub>2</sub>, 0.2% BSA, and pH 7.4) preheated to 37&#x000b0;C for 15&#x02009;min. The incubation buffer contained either 1&#x02009;&#x003bc;M non&#x02010;radiolabelled CP55.940 for NSB wells, or 0.1&#x02009;&#x003bc;M SR141716 for SR1 wells.<xref rid="biof2122-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref>, <xref rid="biof2122-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref> Subsequently, 2.5&#x02009;nM [<sup>3</sup>H]CP55.940 was added to all wells, and the plates were incubated for 1&#x02009;h at 37&#x000b0;C. This step allowed the radiolabeled ligand to compete with the pre&#x02010;incubated ligands for binding sites on the CB<sub>1</sub> receptors. Then, the buffer was removed and the cells were washed again with an ice&#x02010;cold washing buffer (50&#x02009;mM Tris&#x02013;HCl, 500&#x02009;mM NaCl, 0.1% BSA, and pH 7.4) to remove unbound radioactive material. Finally, 0.5&#x02009;M NaOH (500&#x02009;&#x003bc;L) was added to each well to lyse the cells. Cell lysates were transferred to 10&#x02009;mL scintillation vials containing liquid scintillation cocktail, and radioactivity was measured by using a scintillation &#x003b2;&#x02010;counter (Tri&#x02010;Carb 2810 TR, Perkin Elmer, Waltham, MA, USA) as previously described.<xref rid="biof2122-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref>
</p></sec><sec id="biof2122-sec-0010"><label>2.8</label><title>
<styled-content style="fixed-case" toggle="no">TRPV1</styled-content> receptor activity assay</title><p>HaCaT cells (1&#x02009;&#x000d7;&#x02009;10<sup>6</sup>&#x02009;cells) in suspension were incubated with 4&#x02009;&#x003bc;M of the selective intracellular fluorescent probe Fluo&#x02010;3 AM containing 0.02% Pluronic F&#x02010;127 in Opti&#x02010;MEM medium, for 15&#x02009;min at 25&#x000b0;C. Then, cells were washed in Tyrode's buffer (145&#x02009;mM NaCl; 2.5&#x02009;mM KCl; 1.5&#x02009;mMCaCl<sub>2</sub>; 1.2&#x02009;mM MgCl; 10&#x02009;mM D&#x02010;glucose, 10&#x02009;mM HEPES, and pH 7.4), resuspended in 2&#x02009;mL of Tyrode's buffer and transferred to the quartz cuvette of the LS50B spectrofluorometer (Perkin Elmer, Waltham, MA, USA). Fluorescence was measured at 25&#x000b0;C (excitation at <italic toggle="yes">&#x003bb;</italic>&#x02009;=&#x02009;488&#x02009;nm; emission at <italic toggle="yes">&#x003bb;</italic>&#x02009;=&#x02009;516&#x02009;nm) from HaCaT cells pre&#x02010;incubated with CBN at 2.5&#x02009;&#x003bc;M, and then stimulated with the selective TRPV1 agonist capsaicin (1&#x02009;&#x003bc;M), as reported.<xref rid="biof2122-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref> TRPV1 activity was expressed as fluorescence intensity (arbitrary units, AU) per 10<sup>6</sup> cells, as reported.<xref rid="biof2122-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref>
</p></sec><sec id="biof2122-sec-0011"><label>2.9</label><title>Enzyme assays</title><sec id="biof2122-sec-0012"><label>2.9.1</label><title>
<styled-content style="fixed-case" toggle="no">NAPE</styled-content>&#x02010;<styled-content style="fixed-case" toggle="no">PLD</styled-content> assay</title><p>HaCaT cells were seeded into six&#x02010;well plates at a density of 4&#x02009;&#x000d7;&#x02009;10<sup>5</sup> per well, incubated overnight, and then treated with CBN at 2.5&#x02009;&#x003bc;M for 24&#x02009;h. Cell pellets were collected and lyzed in a reaction mixture containing 50&#x02009;mM Tris&#x02013;HCl, 0.05% Triton X&#x02010;100 pH 8.0, and 10&#x02009;&#x003bc;M of fluorogenic substrate PED6. Cell homogenates were pre&#x02010;incubated with the specific NAPE&#x02010;PLD inhibitor ARN19874 at 3.8&#x02009;mM<xref rid="biof2122-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref> for 30&#x02009;min at room temperature, to fully erase enzyme activity as a control. Fluorescence values were measured with excitation at <italic toggle="yes">&#x003bb;</italic>&#x02009;=&#x02009;485&#x02013;488&#x02009;nm, and emission at <italic toggle="yes">&#x003bb;</italic>&#x02009;=&#x02009;530&#x02009;nm at 37&#x000b0;C, by means of continuity kinetics with 30&#x02010;s intervals for 30&#x02009;min in an Enspire multimode plate reader (Perkin Elmer, Waltham, MA, USA), as reported.<xref rid="biof2122-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref> NAPE&#x02010;PLD activity was expressed as fluorescence intensity (arbitrary units, AU) per min per mg of protein, as reported.<xref rid="biof2122-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref>
</p></sec><sec id="biof2122-sec-0013"><label>2.9.2</label><title>
<styled-content style="fixed-case" toggle="no">FAAH</styled-content> assay</title><p>HaCaT cells were seeded into six&#x02010;well plates at a density of 4&#x02009;&#x000d7;&#x02009;10<sup>5</sup> per well, incubated overnight, and then treated with CBN at 2.5&#x02009;&#x003bc;M for 24&#x02009;h. Cell pellets were collected and FAAH activity was determined in membranes isolated from these cells. Briefly, membranes were incubated with 10&#x02009;&#x003bc;M [<sup>3</sup>H]AEA and 50&#x02009;mM Tris&#x02013;HCl, 0.05% BSA at pH 7.4 at 37&#x000b0;C in water bath for 30&#x02009;min. The reaction was blocked with 1&#x02009;mL chloroform/methanol (1:1; v/v) and centrifuged to 900<italic toggle="yes">g</italic> for 10&#x02009;min at 4&#x000b0;C. The aqueous (top) layer was collected and transferred into scintillation vials. The amount of [3H]ethanolamine released was expressed as pmol per min per mg of protein, as reported.<xref rid="biof2122-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref>
</p></sec><sec id="biof2122-sec-0014"><label>2.9.3</label><title>
<styled-content style="fixed-case" toggle="no">DAGL&#x003b1;</styled-content>/&#x003b2; assay</title><p>HaCaT cells were seeded into six&#x02010;well plates at a density of 4&#x02009;&#x000d7;&#x02009;10<sup>5</sup> per well, incubated overnight, and then treated with CBN at 2.5&#x02009;&#x003bc;M for 24&#x02009;h. Cell pellets were collected and DAGL&#x003b1;/&#x003b2; activity was determined in membranes isolated from these cells, by using the synthetic substrate pNPB (8&#x02009;mM) in 50&#x02009;mM HEPES pH 7.3, at room temperature for 20&#x02009;min.<xref rid="biof2122-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref> The DAGL&#x003b1;/&#x003b2; inhibitor KT172 (1&#x02009;&#x003bc;M) was used to full erase enzyme activity as a control, as reported.<xref rid="biof2122-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref>
</p></sec><sec id="biof2122-sec-0015"><label>2.9.4</label><title>
<styled-content style="fixed-case" toggle="no">MAGL</styled-content> assay</title><p>HaCaT cells were seeded into six&#x02010;well plates at a density of 4&#x02009;&#x000d7;&#x02009;10<sup>5</sup> per well, incubated overnight, and then treated with CBN at 2.5&#x02009;&#x003bc;M for 24&#x02009;h. Cell pellets were collected and MAGL activity was determined in membranes isolated from these cells, by using the synthetic substrate arachidonoyl&#x02010;1&#x02010;thio&#x02010;glycerol (200&#x02009;&#x003bc;M) in 10&#x02009;mM Tris/1&#x02009;mM EDTA pH 7.2, at 4&#x000b0;C for 15&#x02009;min, and the MAGL inhibitor JZL184 (4&#x02009;&#x003bc;M), to full erase enzyme activity, as reported.<xref rid="biof2122-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref>
</p></sec></sec><sec id="biof2122-sec-0016"><label>2.10</label><title>Enzyme&#x02010;linked immunosorbent assay</title><p>HaCaT cells were seeded into 12&#x02010;well plates at a density of 2&#x02009;&#x000d7;&#x02009;10<sup>5</sup> per well, incubated overnight and then treated as follows: untreated (control) cells, 2.5&#x02009;&#x003bc;M CBN, 5.0&#x02009;&#x003bc;g/mL LPS, 10&#x02009;&#x003bc;M HC, and 2.5&#x02009;&#x003bc;M CBN. In addition, HaCaT cells were exposed to CBN in combination with the selective CB<sub>1</sub> and TRPV1 antagonists (SR141716A at 0.1&#x02009;&#x003bc;M and CPZ at 5.0&#x02009;&#x003bc;M, respectively) for 24&#x02009;h in the case of IL&#x02010;31 and for 48&#x02009;h in the case of IL&#x02010;12. After each treatment, supernatants (medium) of each condition were collected, centrifuged at 4&#x000b0;C at 300<italic toggle="yes">g</italic> for 5&#x02009;min and stored at &#x02212;80&#x000b0;C until the assay. Cytokine quantification was performed using the DuoSet ELISA kit (#DY201, #DY208, #DY217B, #DY1270, and #DY2824, R&#x00026;D Systems, Minneapolis, MN, USA), following the manufacturer's instructions. Briefly, 96&#x02010;well plates were coated overnight with the specific capture antibody for each interleukin and then blocked with 1% BSA. Selective standard proteins in duplicate and samples in triplicate were added and incubated for 2&#x02009;h. The standard curve for each interleukin was generated by using serially diluted standard proteins at known concentrations as provided by the manufacturer, and the calibration curves obtained were used to interpolate sample values. Each well with standards and/or samples was incubated with the specific detection antibody for 2&#x02009;h. The streptavidin&#x02013;HRP was added and incubated for 20&#x02009;min, followed by the substrate solution for another 20&#x02009;min, and then the reaction was stopped with the specific Stop Solution (1&#x02009;M H<sub>2</sub>SO<sub>4</sub>). Optical densities were determined using an Enspire microplate reader (Perkin Elmer, Waltham, MA, USA) at the specific wavelengths of 450 and 570&#x02009;nm, as reported.<xref rid="biof2122-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref>
</p></sec><sec id="biof2122-sec-0017"><label>2.11</label><title>
<styled-content style="fixed-case" toggle="no">MAPK</styled-content> signaling pathway array</title><p>HaCaT cells were seeded into 100&#x02009;mm plates at a density of 8&#x02009;&#x000d7;&#x02009;10<sup>5</sup> per well, incubated overnight and then exposed to 24&#x02009;h treatment with LPS at 5.0&#x02009;&#x003bc;g/mL, positive control HC at 10&#x02009;&#x003bc;M, CBN at 2.5&#x02009;&#x003bc;M both alone and in combination with the selective CB<sub>1</sub> and TRPV1 antagonists (SR141716A at 0.1&#x02009;&#x003bc;M and CPZ at 5.0&#x02009;&#x003bc;M, respectively). The signaling pathway was analysed through a C&#x02010;Series Human/Mouse MAPK phosphorylation array, according to manufacturer recommendations (#AAH&#x02010;MAPK&#x02010;1&#x02010;8, RayBiotech Inc., Peachtree Corners, GA, USA). Briefly, proteins were extracted from HaCaT cell pellets and quantified using the BCA method. 500&#x02009;&#x003bc;g of proteins were added into each nitrocellulose membrane coated with the specific antibody and incubated overnight at 4&#x000b0;C. The day after, each well was incubated with the specific detection antibody and with streptavidin&#x02013;HRP for 2&#x02009;h at room temperature. Chemiluminescent readings were taken using a C&#x02010;DiGit Blot Scanner (LI&#x02010;COR Bioscience, Lincoln, NE, USA), and densitometry data were extracted using Image Studio&#x02122; software (LI&#x02010;COR Bioscience, Lincoln, NE, USA). Readings were normalized to the positive loading controls, and the membrane background signal was subtracted, as reported.<xref rid="biof2122-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref>
</p></sec><sec id="biof2122-sec-0018"><label>2.12</label><title>Statistical analysis</title><p>Data were analysed using the GraphPad Prism 8 program (GraphPad Software, La Jolla, CA, USA) and were reported as means&#x02009;&#x000b1;&#x02009;SEM of three independent experiments. Statistical analysis was performed using the unpaired <italic toggle="yes">t</italic>&#x02010;test, multiple <italic toggle="yes">t</italic>&#x02010;test, and the one&#x02010;way analysis of variance (ANOVA), according to the data set, followed by a Bonferroni post&#x02010;hoc test. A value of <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results" id="biof2122-sec-0019"><label>3</label><title>RESULTS</title><sec id="biof2122-sec-0020"><label>3.1</label><title>
<styled-content style="fixed-case" toggle="no">CBN</styled-content> modulates distinct <styled-content style="fixed-case" toggle="no">ECS</styled-content> elements at gene and protein levels</title><p>First, different concentrations of CBN&#x02014;from 0.5 to 25&#x02009;&#x003bc;M&#x02014;were tested at three timepoints&#x02014;6, 12, and 24&#x02009;h&#x02014;on HaCaT cells, through cell viability and apoptosis assays (Figure&#x000a0;<xref rid="biof2122-supitem-0001" ref-type="supplementary-material">S1</xref>). A dose&#x02013;response curve was plotted to determine the half&#x02010;maximal inhibitory concentration (IC<sub>50</sub>) of CBN at each timepoint, as indicated in Table&#x000a0;<xref rid="biof2122-supitem-0001" ref-type="supplementary-material">S1</xref>. Based on these preliminary data, the non&#x02010;cytotoxic dose of 2.5&#x02009;&#x003bc;M at 24&#x02009;h (i.e., half of the calculated IC<sub>50</sub>) was selected to perform all subsequent analyses. Thus, the expression of ECS elements [eCB&#x02010;binding receptors (CB<sub>1</sub>, CB<sub>2</sub>, GPR55, TRPV1, and PPAR&#x003b1;/&#x003b3;/&#x003b4;), and the main AEA (NAPE&#x02010;PLD, FAAH), and 2&#x02010;AG (DAGL&#x003b1;/&#x003b2;, MAGL) metabolic enzymes] was evaluated, at both mRNA&#x02014;through quantitative real&#x02010;time polymerase chain reaction (RT&#x02010;qPCR)&#x02014;and protein level&#x02014;through Western blotting&#x02014;in HaCaT cells after treatment with 2.5&#x02009;&#x003bc;M CBN for 24&#x02009;h. Notably, no alterations were found at gene level for any of the ECS elements tested, with the exception of CB<sub>1</sub> which was significantly increased by CBN compared to control cells (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.01 vs. CTRL) (Figure&#x000a0;<xref rid="biof2122-fig-0001" ref-type="fig">1</xref>).</p><fig position="float" fig-type="FIGURE" id="biof2122-fig-0001"><label>FIGURE 1</label><caption><p>Gene expression of (A) eCB&#x02010;binding receptors (CB<sub>1</sub>, CB<sub>2</sub>, GPR55, TRPV1, and PPAR&#x003b1;/&#x003b3;/&#x003b4;) and (B) eCBs metabolic enzymes (NAPE&#x02010;PLD, FAAH, DAGL&#x003b1;/&#x003b2;, and MAGL) in HaCaT cells following 24&#x02009;h treatment with 2.5&#x02009;&#x003bc;M CBN. The values were expressed as 2<sup>(&#x02212;&#x00394;&#x00394;<italic toggle="yes">C</italic>t)</sup> and normalized to &#x003b2;&#x02010;actin and GAPDH as housekeeping genes. Data are the mean&#x02009;&#x000b1;&#x02009;SEM of three independent experiments (<italic toggle="yes">n</italic>&#x02009;=&#x02009;3). Statistical analysis was performed using a multiple <italic toggle="yes">t</italic>&#x02010;test, followed by the correction with the Bonferroni&#x02013;Dunn method (**<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.01 vs. control).</p></caption><graphic xlink:href="BIOF-51-0-g001" position="anchor" id="jats-graphic-3"/></fig><p>As for the protein expression, only that of TRPV1 was significantly increased (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.01 and <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05, respectively vs. CTRL) in HaCaT cells exposed to 2.5&#x02009;&#x003bc;M CBN, while the other ECS components remained unaffected under the same experimental conditions (Figure&#x000a0;<xref rid="biof2122-fig-0002" ref-type="fig">2</xref>).</p><fig position="float" fig-type="FIGURE" id="biof2122-fig-0002"><label>FIGURE 2</label><caption><p>Protein expression of (A) eCBs&#x02010;binding receptors (CB<sub>1</sub>, CB<sub>2</sub>, GPR55, TRPV1, and PPAR&#x003b1;/&#x003b3;/&#x003b4;) and (B) metabolic enzymes (NAPE&#x02010;PLD, FAAH, DAGL&#x003b1;/&#x003b2;, and MAGL) in HaCaT cells following 24&#x02009;h treatment with 2.5&#x02009;&#x003bc;M CBN. Densitometric analyses of immunoreactive bands were normalized to &#x003b2;&#x02010;actin as housekeeping protein. Data are the mean&#x02009;&#x000b1;&#x02009;SEM of three independent experiments (<italic toggle="yes">n</italic>&#x02009;=&#x02009;3). Statistical analysis was performed using a multiple <italic toggle="yes">t</italic>&#x02010;test, followed by the correction with the Bonferroni&#x02013;Dunn method (**<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.01 vs. control). Representative bands of the main ECS components are shown in the lower panels.</p></caption><graphic xlink:href="BIOF-51-0-g008" position="anchor" id="jats-graphic-5"/></fig></sec><sec id="biof2122-sec-0021"><label>3.2</label><title>
<styled-content style="fixed-case" toggle="no">CBN</styled-content> modulates <styled-content style="fixed-case" toggle="no">ECS</styled-content> at the functional level</title><p>Then, the effect of CBN on functional activity of specific eCBs&#x02010;binding receptors and eCBs metabolic enzymes was investigated. In particular, the modulation of TRPV1 channel and CB<sub>1</sub> receptor was assessed through specific intracellular Ca<sup>2+</sup> release and radioligand binding assays, respectively. TRPV1 was activated by CBN in HaCaT cells, as shown by the significant increase in the calcium indicator (Fluo 3&#x02010;AM) fluorescence intensity in CBN&#x02010;treated cells (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05 vs. CTRL) (Figure&#x000a0;<xref rid="biof2122-fig-0003" ref-type="fig">3A</xref>). Similarly, the CBN&#x02010;mediated activation of CB<sub>1</sub> receptor was demonstrated by the significant increase (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001 vs. CTRL) in the binding activity, up to 3&#x02010;fold compared to control cells (Figure&#x000a0;<xref rid="biof2122-fig-0003" ref-type="fig">3B</xref>).</p><fig position="float" fig-type="FIGURE" id="biof2122-fig-0003"><label>FIGURE 3</label><caption><p>(A) Intracellular Ca<sup>2+</sup> release triggered by capsaicin (a selective agonist of TRPV1) in HaCaT cells following 24&#x02009;h treatment with 2.5&#x02009;&#x003bc;M CBN. Data are means&#x02009;&#x000b1;&#x02009;SEM of three independent experiments (<italic toggle="yes">n</italic>&#x02009;=&#x02009;3). Statistical analysis was performed using an unpaired <italic toggle="yes">t</italic>&#x02010;test (*<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05 vs. control). (B) CB<sub>1</sub> binding activity in HaCaT cells following 24&#x02009;h treatment with 2.5&#x02009;&#x003bc;M CBN. Data are the mean&#x02009;&#x000b1;&#x02009;SEM of three independent experiments (<italic toggle="yes">n</italic>&#x02009;=&#x02009;3). Statistical analysis was performed using an unpaired <italic toggle="yes">t</italic>&#x02010;test (***<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001 vs. control).</p></caption><graphic xlink:href="BIOF-51-0-g007" position="anchor" id="jats-graphic-7"/></fig><p>The activity of AEA and 2&#x02010;AG metabolic enzymes was evaluated through specific enzymatic assays under the same experimental conditions. At 2.5&#x02009;&#x003bc;M, CBN stimulated AEA metabolism since both NAPE&#x02010;PLD and FAAH activities increased in HaCaT cells compared to controls (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05 and <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.01, respectively vs. CTRL) (Figure&#x000a0;<xref rid="biof2122-fig-0004" ref-type="fig">4A,B</xref>). As for 2&#x02010;AG metabolism, MAGL activity was significantly increased by CBN (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001 vs. CTRL), while no changes were observed for DAGL&#x003b1;/&#x003b2; activity (Figure&#x000a0;<xref rid="biof2122-fig-0004" ref-type="fig">4C,D</xref>).</p><fig position="float" fig-type="FIGURE" id="biof2122-fig-0004"><label>FIGURE 4</label><caption><p>Activity of eCBs&#x02010;metabolic enzymes: (A) NAPE&#x02010;PLD, (B) FAAH, (C) DAGL&#x003b1;/&#x003b2;, and (D) MAGL, in HaCaT cells following 24&#x02009;h treatment with 2.5&#x02009;&#x003bc;M CBN. Data are the mean&#x02009;&#x000b1;&#x02009;SEM of three independent experiments (<italic toggle="yes">n</italic>&#x02009;=&#x02009;3). Statistical analysis was performed using an unpaired <italic toggle="yes">t</italic>&#x02010;test (*<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.01, and ***<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001 vs. control).</p></caption><graphic xlink:href="BIOF-51-0-g004" position="anchor" id="jats-graphic-9"/></fig></sec><sec id="biof2122-sec-0022"><label>3.3</label><title>
<styled-content style="fixed-case" toggle="no">CBN</styled-content> prevents keratinocyte inflammation via <styled-content style="fixed-case" toggle="no">TRPV1</styled-content>
</title><p>To ascertain whether CBN may have anti&#x02010;inflammatory properties in human keratinocytes, as previously shown for other pCBs,<xref rid="biof2122-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> the release of pro&#x02010;inflammatory ILs (IL&#x02010;1&#x003b2;, IL&#x02010;8, IL&#x02010;12, and IL&#x02010;31), and of the anti&#x02010;inflammatory IL&#x02010;10 was analysed through enzyme&#x02010;linked immunosorbent (ELISA) assay in inflamed HaCaT cells exposed to 5.0&#x02009;&#x003bc;g/mL of LPS, with or without 2.5&#x02009;&#x003bc;M CBN for 24 and 48&#x02009;h, which represents the two timepoints previously used to set&#x02010;up the in vitro inflammatory model of keratinocytes.<xref rid="biof2122-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> LPS treatment markedly increased the levels of all pro&#x02010;inflammatory cytokines, except for IL&#x02010;1&#x003b2; and for IL&#x02010;12 at 24&#x02009;h. Notably, 2.5&#x02009;&#x003bc;M CBN in combination with LPS significantly reverted the increase of IL&#x02010;8 (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.01 vs. LPS) at 24&#x02009;h of treatment, although to a lesser extent than the anti&#x02010;inflammatory compound hydrocortisone (HC), used as a positive control (Figure&#x000a0;<xref rid="biof2122-fig-0005" ref-type="fig">5A,B</xref>). The anti&#x02010;inflammatory action of 2.5&#x02009;&#x003bc;M CBN was more effective on IL&#x02010;12 and IL&#x02010;31 levels; indeed, 2.5&#x02009;&#x003bc;M CBN significantly reverted the LPS&#x02010;mediated increase in IL&#x02010;12 (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001 vs. LPS) and IL&#x02010;31 (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.01 vs. LPS) at 48 and 24&#x02009;h, respectively, much alike HC (Figure&#x000a0;<xref rid="biof2122-fig-0005" ref-type="fig">5C,D</xref>). In addition, IL&#x02010;31 levels were reduced by CBN at 48&#x02009;h, yet in a non&#x02010;significant manner (Figure&#x000a0;<xref rid="biof2122-fig-0005" ref-type="fig">5D</xref>). Moreover, the anti&#x02010;inflammatory IL&#x02010;10 was weakly modulated by LPS alone, whereas 2.5&#x02009;&#x003bc;M CBN significantly increased its level (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.01 vs. LPS) when cells were exposed to both LPS and CBN for 48&#x02009;h (Figure&#x000a0;<xref rid="biof2122-fig-0005" ref-type="fig">5E</xref>). Incidentally, treatment of HaCaT cells with CBN alone did not significantly affect the release of any of the tested cytokines (Figure&#x000a0;<xref rid="biof2122-fig-0005" ref-type="fig">5</xref>).</p><fig position="float" fig-type="FIGURE" id="biof2122-fig-0005"><label>FIGURE 5</label><caption><p>Release of ILs after HaCaT cells exposure to 2.5&#x02009;&#x003bc;M CBN alone, 5.0&#x02009;&#x003bc;g/mL LPS, 10&#x02009;&#x003bc;M HC, and 2.5&#x02009;&#x003bc;M CBN in the presence of LPS for 24 and 48h. (A) IL&#x02010;1&#x003b2; expression (pg/mL); (B) IL&#x02010;8 expression (ng/mL); (C) IL&#x02010;12 expression (pg/mL); (D) IL&#x02010;31 expression (pg/mL); and (E) IL&#x02010;10 expression (pg/mL). Data are presented as the mean&#x02009;&#x000b1;&#x02009;SEM of three independent experiments (<italic toggle="yes">n</italic>&#x02009;=&#x02009;3). Statistical analysis was performed using a one&#x02010;way ANOVA test followed by a Bonferroni post hoc test (**<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001, ****<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.0001 vs. CTRL; <sup>#</sup>
<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05, <sup>##</sup>
<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.01, <sup>###</sup>
<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001, <sup>####</sup>
<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.0001 vs. LPS).</p></caption><graphic xlink:href="BIOF-51-0-g003" position="anchor" id="jats-graphic-11"/></fig><p>To further investigate whether CBN may regulate IL&#x02010;12 and IL&#x02010;31 release in an ECS&#x02010;dependent manner, HaCaT cells were pretreated also with SR141716A (SR1)&#x02014;selective antagonist of CB<sub>1</sub>&#x02014;and capsazepine (CPZ)&#x02014;selective TRPV1 antagonist&#x02014;under inflammatory conditions (Figure&#x000a0;<xref rid="biof2122-fig-0006" ref-type="fig">6A,B</xref>). Interestingly, CPZ significantly restored the anti&#x02010;inflammatory effect of CBN on IL&#x02010;31 release (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05 vs. CBN) in HaCaT cells exposed to LPS for 48&#x02009;h, suggesting an engagement of TRPV1 (Figure&#x000a0;<xref rid="biof2122-fig-0006" ref-type="fig">6A</xref>). Instead, the action of CBN on IL&#x02010;12 was not mediated by CB<sub>1</sub> nor by TRPV1, as the reduction of IL&#x02010;12 caused by CBN was not affected by either SR1 or CPZ (Figure&#x000a0;<xref rid="biof2122-fig-0006" ref-type="fig">6B</xref>).</p><fig position="float" fig-type="FIGURE" id="biof2122-fig-0006"><label>FIGURE 6</label><caption><p>Release of ILs after HaCaT cells exposure to 5.0&#x02009;&#x003bc;g/mL LPS, 10&#x02009;&#x003bc;M HC, 2.5&#x02009;&#x003bc;M CBN alone or in combination with the two selective antagonists for CB<sub>1</sub> (SR1 at 0.1&#x02009;&#x003bc;M) and TRPV1 (CPZ at 5.0&#x02009;&#x003bc;M). (A) IL&#x02010;31 expression (pg/mL) after 24&#x02009;h treatment and (B) IL&#x02010;12 expression (pg/mL) after 48&#x02009;h treatment. Data are presented as the mean&#x02009;&#x000b1;&#x02009;SEM of three independent experiments (<italic toggle="yes">n</italic>&#x02009;=&#x02009;3). Statistical analysis was performed using a one&#x02010;way ANOVA test followed by a Bonferroni post hoc test (***<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001, ****<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.0001 vs. CTRL; <sup>#</sup>
<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05, <sup>##</sup>
<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.01, <sup>###</sup>
<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001 vs. LPS; <sup>$</sup>
<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05 vs. CBN).</p></caption><graphic xlink:href="BIOF-51-0-g005" position="anchor" id="jats-graphic-13"/></fig></sec><sec id="biof2122-sec-0023"><label>3.4</label><title>Expression of mitogen&#x02010;activated protein kinases in inflamed keratinocytes</title><p>Since mitogen&#x02010;activated protein kinases (MAPK) pathway regulates the inflammatory responses of several cell types&#x02014;keratinocytes included,<xref rid="biof2122-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref> the expression of 17 proteins of the MAPK signaling route was investigated in inflamed HaCaT cells exposed to CBN, alone or in combination with selective CB<sub>1</sub> and TRPV1 antagonists, by using a human phosphorylation array (for details see Figure&#x000a0;<xref rid="biof2122-supitem-0001" ref-type="supplementary-material">S2</xref>). The overall expression pattern of phosphorylated MAPK proteins was found to be low under most experimental conditions, apart from glycogen synthase kinase 3&#x003b2; (GSK3&#x003b2;) that was high in all experimental groups (Figure&#x000a0;<xref rid="biof2122-fig-0007" ref-type="fig">7</xref>). Of note, GSK3&#x003b2; is the only MAPK analysed to be inactive in the phosphorylated form,<xref rid="biof2122-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref> and its expression was found to be modulated (yet not significantly) under all experimental conditions (Figure&#x000a0;<xref rid="biof2122-fig-0007" ref-type="fig">7</xref>). As for the other MAPK proteins, only minor alterations in the expression of cyclic adenosine monophosphate response element&#x02010;binding protein (CREB), heat shock protein 27 (HSP27), p38 mitogen&#x02010;activated protein kinase (p38), and tumor protein p53 (p53) were observed in inflamed HaCaT cells treated with CBN in the presence of SR1 or CPZ, compared to LPS alone (Figure&#x000a0;<xref rid="biof2122-fig-0007" ref-type="fig">7</xref>).</p><fig position="float" fig-type="FIGURE" id="biof2122-fig-0007"><label>FIGURE 7</label><caption><p>Heat map of the most relevant 17 proteins of the MAPK signaling pathway in HaCaT cells following 24&#x02009;h treatment with LPS (5.0&#x02009;&#x003bc;g/mL) in the presence of 2.5&#x02009;&#x003bc;M CBN, alone or in combination with the two selective antagonists for CB<sub>1</sub> (SR1 at 0.1&#x02009;&#x003bc;M) and TRPV1 (CPZ at 5.0&#x02009;&#x003bc;M). Samples were analyzed through the human phosphorylation array, and data are expressed as means of three sets of experiments for each condition (<italic toggle="yes">n</italic>&#x02009;=&#x02009;3).</p></caption><graphic xlink:href="BIOF-51-0-g006" position="anchor" id="jats-graphic-15"/></fig></sec></sec><sec id="biof2122-sec-0024"><label>4</label><title>DISCUSSION AND CONCLUSION</title><p>To date, the effects of cannabis on skin physiology and pathology have focused on the main pCBs CBD and THC,<xref rid="biof2122-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref>, <xref rid="biof2122-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref>, <xref rid="biof2122-bib-0053" ref-type="bibr">
<sup>53</sup>
</xref> while little is known about minor pCBs like CBN. Recently, we have shown that non&#x02010;psychotropic pCBs CBG, CBC, THCV, and CBGA differently modulate gene and protein expression of distinct ECS elements, as well as their functional activity in HaCaT cells.<xref rid="biof2122-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> In line with this, here we demonstrate that in the same human keratinocytes CBN&#x02014;used at a non&#x02010;cytotoxic half&#x02010;IC<sub>50</sub> dose&#x02014;increases gene and protein expression of specific eCBs&#x02010;biding receptors (i.e., CB<sub>1</sub> and TRPV1, respectively), without modulating gene and protein expression of metabolic enzymes of these endogenous lipids. Of note, differences between gene and protein expression of ECS elements are not unprecedented.<xref rid="biof2122-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>, <xref rid="biof2122-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref>, <xref rid="biof2122-bib-0054" ref-type="bibr">
<sup>54</sup>
</xref>, <xref rid="biof2122-bib-0055" ref-type="bibr">
<sup>55</sup>
</xref> Such discrepancies may be due to distinct half&#x02010;lives of mRNAs and proteins, which are caused by different degrading processes<xref rid="biof2122-bib-0056" ref-type="bibr">
<sup>56</sup>
</xref> that lead to independent stability profiles.<xref rid="biof2122-bib-0057" ref-type="bibr">
<sup>57</sup>
</xref>, <xref rid="biof2122-bib-0058" ref-type="bibr">
<sup>58</sup>
</xref> At the functional level, CBN upregulates AEA metabolism, by stimulating the activity of NAPE&#x02010;PLD and FAAH, and promotes the activity of the degradative enzyme of 2&#x02010;AG, MAGL, but not that of its biosynthetic enzymes DAGL&#x003b1;/&#x003b2;. In addition, our functional data show that CB<sub>1</sub> binding is significantly increased by CBN, a finding that is in keeping with previous literature data showing CBN activity on CB<sub>1</sub> in monkey kidney (COS&#x02010;7) transfected cells, as well as in rat brain synaptosomal preparations.<xref rid="biof2122-bib-0059" ref-type="bibr">
<sup>59</sup>
</xref> The engagement of TRPV1 by CBN was also investigated, because CBN was shown to be weakly effective on TRPV1, relatively potent on the transient receptor potential ankyrin 1 (TRPA1), and only weakly active on the TRP vanilloid receptor 2 (TRPV2) in HEK&#x02010;293 cells stably overexpressing recombinant rat or human TRP channels.<xref rid="biof2122-bib-0060" ref-type="bibr">
<sup>60</sup>
</xref> Our present data extend previous findings to human keratinocytes, that constitutively express the TRPV1 channel, supporting the concept that CBN may have a promising pharmacological profile for skin&#x02010;related conditions by engaging this eCBs&#x02010;binding receptor channel. In line with this, we investigated the effects of CBN in an inflamed keratinocyte model consisting of HaCaT cells exposed to LPS.<xref rid="biof2122-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> It is well known that the process of inflammation is orchestrated by inflammatory mediators, and a typical response evoked by pCBs is the dysregulation of cytokine production by immune cells with an unbalance between those produced by T&#x02010;helper subsets Th1 and Th2.<xref rid="biof2122-bib-0061" ref-type="bibr">
<sup>61</sup>
</xref>, <xref rid="biof2122-bib-0062" ref-type="bibr">
<sup>62</sup>
</xref> Here, we chose to evaluate the effect of CBN in our inflamed keratinocytes model on the release of some of the main cytokines known to be involved in the pathogenesis of skin diseases.<xref rid="biof2122-bib-0063" ref-type="bibr">
<sup>63</sup>
</xref> Consistently, we found a reduction by CBN in the release of some pro&#x02010;inflammatory ILs at different time points of HaCaT stimulation (i.e., IL&#x02010;8 and IL&#x02010;31 at 24&#x02009;h and IL&#x02010;12 at 48&#x02009;h), while an increase of anti&#x02010;inflammatory IL&#x02010;10 release at 48&#x02009;h. Among these, IL&#x02010;12 is a key cytokine involved in the regulation of epidermal functions,<xref rid="biof2122-bib-0064" ref-type="bibr">
<sup>64</sup>
</xref> with possible inflammatory<xref rid="biof2122-bib-0065" ref-type="bibr">
<sup>65</sup>
</xref> and protective<xref rid="biof2122-bib-0066" ref-type="bibr">
<sup>66</sup>
</xref>, <xref rid="biof2122-bib-0067" ref-type="bibr">
<sup>67</sup>
</xref> roles in the skin. The increase in the IL&#x02010;12p70 release in psoriasis and during the chronic phase of atopic dermatitis is thought to be responsible for controling the immune and inflammatory response, by promoting the differentiation of Th0 lymphocytes into Th1&#x02010;type cells.<xref rid="biof2122-bib-0067" ref-type="bibr">
<sup>67</sup>
</xref>, <xref rid="biof2122-bib-0068" ref-type="bibr">
<sup>68</sup>
</xref>, <xref rid="biof2122-bib-0069" ref-type="bibr">
<sup>69</sup>
</xref> On the other hand, recent studies suggested a protective effect of IL&#x02010;12 in a psoriatic mouse model, due to the activation of a transcriptional programme that limits skin inflammation by engaging IL&#x02010;12 receptor signaling.<xref rid="biof2122-bib-0066" ref-type="bibr">
<sup>66</sup>
</xref> Our data showed an increase in IL&#x02010;12 levels under inflammatory conditions, thus corroborating its role in inflammation, that was reverted by CBN. Moreover, IL&#x02010;31 is one of the most relevant cytokines in the context of the pathogenesis of pruritus.<xref rid="biof2122-bib-0070" ref-type="bibr">
<sup>70</sup>
</xref>, <xref rid="biof2122-bib-0071" ref-type="bibr">
<sup>71</sup>
</xref> Indeed, IL&#x02010;31 expression was found to be increased in lesional and non&#x02010;lesional skin of patients with atopic dermatitis,<xref rid="biof2122-bib-0072" ref-type="bibr">
<sup>72</sup>
</xref>, <xref rid="biof2122-bib-0073" ref-type="bibr">
<sup>73</sup>
</xref>, <xref rid="biof2122-bib-0074" ref-type="bibr">
<sup>74</sup>
</xref> and it is able to induce severe pruritus in mice where levels of IL&#x02010;31 correlated with scratching behaviour.<xref rid="biof2122-bib-0075" ref-type="bibr">
<sup>75</sup>
</xref> In addition to its pruritogenic function, IL&#x02010;31 also directly inhibits keratinocyte differentiation by downregulating the expression of proteins involved in barrier and differentiation processes, overall leading to the disruption of the epidermal barrier function.<xref rid="biof2122-bib-0076" ref-type="bibr">
<sup>76</sup>
</xref>, <xref rid="biof2122-bib-0077" ref-type="bibr">
<sup>77</sup>
</xref>, <xref rid="biof2122-bib-0078" ref-type="bibr">
<sup>78</sup>
</xref> In the light of the preminent role of IL&#x02010;31 in skin inflammation, the ability of CBN to decrease its secretion appears noteworthy. More in general, the ability of CBN to decrease or increase the pro&#x02010; and anti&#x02010;inflammatory outputs has been previously reported in different paradigms, for example in a murine model of ovalbumin&#x02010;sensitized allergic asthma where CBN blocked the production of ILs 2, 4, 5, 13 and decreased allergen mucus production.<xref rid="biof2122-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> Similarly, CBN was shown to inhibit pro&#x02010;inflammatory cytokine production from oral bacteria&#x02010;exposed human monocytes and epithelial cells.<xref rid="biof2122-bib-0079" ref-type="bibr">
<sup>79</sup>
</xref> More recently, CBN was also found to exert anti&#x02010;inflammatory effects by influencing different stages of gene expression: transcription, post&#x02010;transcriptional regulation, translation, and post&#x02010;translational regulation in human macrophages.<xref rid="biof2122-bib-0080" ref-type="bibr">
<sup>80</sup>
</xref> It should be recalled that pCBs and pCB&#x02010;like compounds have proven potent anti&#x02010;inflammatory activity through mechanisms that are not yet fully understood. Under some circumstances, activation of CB<sub>1/2</sub> receptors provides anti&#x02010;inflammatory responses, and particularly CB<sub>2</sub> appears to be the main player in allergic contact dermatitis<xref rid="biof2122-bib-0081" ref-type="bibr">
<sup>81</sup>
</xref>, <xref rid="biof2122-bib-0082" ref-type="bibr">
<sup>82</sup>
</xref> and immune suppression of oral pathogens, where a CB<sub>2</sub>/phosphoinositide 3&#x02010;kinase (PI3K) axis is activated by CBN (as well as by CBD and THC).<xref rid="biof2122-bib-0079" ref-type="bibr">
<sup>79</sup>
</xref> Conversely, CB<sub>1/2</sub> receptors may not even be engaged in these processes, as demonstrated by a study where the topical application of THC effectively improved allergic contact dermatitis in both wild&#x02010;type and CB<sub>1</sub>/CB<sub>2</sub>&#x02010;deficient mice.<xref rid="biof2122-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref> In order to fill this gap knowledge, we decided to focus the attention on IL&#x02010;12 and IL&#x02010;31 to interrogate a possible correlation with the ECS. In this context, we previously observed beneficial effects induced by other minor pCBs (e.g., cannabigerol, cannabichromene, &#x00394;<sup>9</sup>&#x02010;tetrahydrocannabivarin, and cannabigerolic acid) on IL&#x02010;31 via ECS involvement.<xref rid="biof2122-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> Here, we obtained similar results with CBN, which was able to revert the inflammatory secretion of IL&#x02010;31 through the TRPV1 channel, while CB<sub>1</sub> did not appear to be involved. Instead, the effects of CBN on the release of IL&#x02010;12 were found to be ECS&#x02010;independent. The correlation between IL&#x02010;31 and TRPV1 channel&#x02014;in the presence of CBN&#x02014;seems to call for particular attention, since TRPV1 is known to have pruritic functions and to increase in atopic dermatitis&#x02010;like skin lesions, both in humans and in a mouse model of psoriasiform dermatitis.<xref rid="biof2122-bib-0083" ref-type="bibr">
<sup>83</sup>
</xref>, <xref rid="biof2122-bib-0084" ref-type="bibr">
<sup>84</sup>
</xref>, <xref rid="biof2122-bib-0085" ref-type="bibr">
<sup>85</sup>
</xref> There is also literature evidence that attests beneficial effects of TRPV1&#x02010;targeting. Notably, the eCB&#x02010;like compound PEA was found to inhibit allergic contact dermatitis in mice, as well as cytokine expression in human HaCaT cells, through TRPV1&#x02010;associated mechanisms.<xref rid="biof2122-bib-0086" ref-type="bibr">
<sup>86</sup>
</xref> In addition, some pCBs stimulate TRPV1 channels, as reported by us and others.<xref rid="biof2122-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref>, <xref rid="biof2122-bib-0060" ref-type="bibr">
<sup>60</sup>
</xref>, <xref rid="biof2122-bib-0087" ref-type="bibr">
<sup>87</sup>
</xref>, <xref rid="biof2122-bib-0088" ref-type="bibr">
<sup>88</sup>
</xref> Overall, these results and the key role of IL&#x02010;31 in inflammatory skin diseases, support the potential of TRPV1&#x02010;targeting (e.g., by CBN) for therapeutic purposes, for instance to treat itch&#x02010;associated skin conditions.<xref rid="biof2122-bib-0089" ref-type="bibr">
<sup>89</sup>
</xref> Interestingly, antibodies against IL&#x02010;31 have shown to ameliorate the scratching behaviour in a mouse model of atopic dermatitis,<xref rid="biof2122-bib-0090" ref-type="bibr">
<sup>90</sup>
</xref> and patients affected by chronic spontaneous urticaria responded to a treatment able to reduce IL&#x02010;31 serum levels.<xref rid="biof2122-bib-0091" ref-type="bibr">
<sup>91</sup>
</xref>
</p><p>In this study, we also sought to elucidate signaling events that could explain the CBN&#x02010;mediated suppression of inflammation by analysing the modulation of phosphorylated proteins of the MAPK pathway. The activation of this pathway by LPS involves a series of phosphorylation events leading to the induction of inflammatory mediators, cytokines included.<xref rid="biof2122-bib-0092" ref-type="bibr">
<sup>92</sup>
</xref>, <xref rid="biof2122-bib-0093" ref-type="bibr">
<sup>93</sup>
</xref> Among the different MAPKs investigated in our inflamed model, the phosphorylated and inactive form of GSK3&#x003b2; appeared to be the most expressed in HaCaT cells under CBN stimulation and all other experimental conditions. A regulatory role of GSK3&#x003b2; in the modulation of inflammation has been already suggested.<xref rid="biof2122-bib-0094" ref-type="bibr">
<sup>94</sup>
</xref>, <xref rid="biof2122-bib-0095" ref-type="bibr">
<sup>95</sup>
</xref> In particular, the knock&#x02010;down of GSK3&#x003b2; was found to significantly reduce LPS&#x02010;associated pro&#x02010;inflammatory cytokines and death of human monocytes. Interestingly, cannabinoids have been reported to suppress neuroinflammation in Alzheimer's disease with a downregulation of phospho&#x02010;GSK3&#x003b2;.<xref rid="biof2122-bib-0096" ref-type="bibr">
<sup>96</sup>
</xref> In contrast, the anti&#x02010;inflammatory signal evoked by CBN (as well as by CBD and THC) to suppress oral pathogens does not appear to be executed via the GSK3&#x003b2;&#x02010;dependent cholinergic anti&#x02010;inflammatory pathway.<xref rid="biof2122-bib-0079" ref-type="bibr">
<sup>79</sup>
</xref> In our study, other phosphorylated active proteins of the MAPK family appear to be involved in the CBN anti&#x02010;inflammatory response, yet to a lesser and non&#x02010;significant extent.</p><p>In summary, in this investigation CBN has been shown to be active on inflamed human keratinocytes via TRPV1 channels, thus supporting a potential therapeutic effect of this minor pCB in the treatment of inflammatory skin diseases. It should be recalled that CBN has been indeed suggested as a potential component of topical applications to be used against psoriasis, where it inhibits keratinocyte proliferation through as yet unclear CB<sub>1/2</sub>&#x02010;independent mechanisms.<xref rid="biof2122-bib-0097" ref-type="bibr">
<sup>97</sup>
</xref> A recent study has also shown anti&#x02010;melanoma, anti&#x02010;melanogenic, and anti&#x02010;tyrosinase properties of CBN (and other pCBs), thus making them useful as novel cosmeceutical products for skin care.<xref rid="biof2122-bib-0098" ref-type="bibr">
<sup>98</sup>
</xref> Moreover, a CBN&#x02010;based therapy has been recently shown to be effective in the treatment of epidermolysis bullosa (EB), a group of rare medical conditions characterized by easy blistering of the skin and mucous membranes.<xref rid="biof2122-bib-0099" ref-type="bibr">
<sup>99</sup>
</xref> This therapy was recently completed in a phase 2 clinical trial, aimed at assessing its potential as a topical treatment for EB, where it may help to relieve hallmark symptoms such as itch in a subset of EB Simplex patients.<xref rid="biof2122-bib-0099" ref-type="bibr">
<sup>99</sup>
</xref> On a final note, it can be recalled that the therapeutic potential of CBN goes beyond the skin, because another CBN&#x02010;based topical eye drop formulation has been demonstrated to be effective in the treatment of glaucoma, where it may prevent the inflammation leading to elevated intraocular pressure and hence damage to the retinal ganglion cells.<xref rid="biof2122-bib-0100" ref-type="bibr">
<sup>100</sup>
</xref>
</p><p>Taken together, our data suggest that CBN may hold true therapeutic potential to treat different human skin diseases. Such a biological activity of CBN occurs through engagement of selected elements of the endocannabinoid system&#x02014;in particular TRPV1&#x02014;a finding that paves the way to the development of distinct formulations of cannabis extracts for selected therapeutic applications.</p></sec><sec id="biof2122-sec-0025"><title>AUTHOR CONTRIBUTIONS</title><p>C. R. and M. M. contributed to conceptualization, writing&#x02010;reviewing and editing. C. D. M. and D. T. worked on validation, draft preparation and visualization. C. D. M, D. T., S. S., F. C., and C. B. A. worked on methodology and investigation. C.D.M, D.T., S.S., F.C, C.B.A. and A.T. worked on formal analysis. C. D. M., D. T., E. H., and S. K. dealt with resources. M. M. was in charge of supervision, project administration, and funding acquisition. All authors reviewed and approved the final version of the manuscript.</p></sec><sec id="biof2122-sec-0026"><title>FUNDING INFORMATION</title><p>This work was supported by InMed Pharmaceuticals Inc. (Vancouver, Canada) under a collaborative research agreement (No. PCI0029) with Professor Mauro Maccarrone. The funder had no role in the design of the study, in the collection, analyses or interpretation of data, nor in the decision to publish the results.</p></sec><sec sec-type="COI-statement" id="biof2122-sec-0027"><title>CONFLICT OF INTEREST STATEMENT</title><p>The authors declare that the InMed Pharmaceuticals is commercializing cannabinoid&#x02010;based therapies. Eric Hsu is the Senior Vice President of this company; Salam Kadhim is a former Senior Scientist of Preclinical R&#x00026;D, and Mauro Maccarrone is a Scientific Advisory Board member.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="biof2122-supitem-0001" position="float" content-type="local-data"><caption><p>
<bold>FIGURE S1:</bold> Cell viability and apoptosis analysis. (A) Viability of HaCaT cells treated with vehicle (CTRL) or increasing concentrations (0.5, 1.0, 2.5, 5.0, 10, and 25&#x02009;&#x003bc;M) of CBN at different timepoints (6, 12, and 24&#x02009;h). Values are plotted as a logarithmic dose&#x02013;response curve used to determine the IC<sub>50</sub> (&#x003bc;M) for CBN at each time point. Data are means&#x02009;&#x000b1;&#x02009;SEM of three independent experiments (<italic toggle="yes">n</italic>&#x02009;=&#x02009;3). (B) Apoptosis of HaCaT cells treated with vehicle (CTRL) or increasing concentrations (0.5, 1.0, 2.5, 5.0, 10, and 25&#x02009;&#x003bc;M) of CBN for 24&#x02009;h. Data are means&#x02009;&#x000b1;&#x02009;SEM of three independent experiments (<italic toggle="yes">n</italic>&#x02009;=&#x02009;3). Statistical analysis was performed by one&#x02010;way ANOVA test followed by Bonferroni <italic toggle="yes">post hoc</italic> test (****<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001 vs. CTRL).</p><p>
<bold>FIGURE S2:</bold> MAPK kinases expression in the inflamed model of keratinocytes. (A) Representative images of phospho&#x02010;kinase arrays for each treatment, captured by C&#x02010;DiGit blot scanner. Each membrane detects the following 17 MAPKs: serine/threonine kinase 1 (AKT); cyclic adenosine monophosphate (cAMP) response element&#x02010;binding protein (CREB); glycogen synthase kinase 3 &#x003b1; (GSK3&#x003b1;) and &#x02010;&#x003b2; (GSK3&#x003b2;); c&#x02010;Jun N&#x02010;terminal kinase (JNK); extracellular signal&#x02010;regulated kinase (ERK1); mitogen&#x02010;activated protein kinase (MEK1); mitogen&#x02010;activated protein kinase kinase 3 (MKK3) and 6 (MKK6); mitogen&#x02010; and stress&#x02010;activated protein kinase 2 (MSK2); heat shock protein 27 (HSP27); mammalian target of rapamycin (mTor); p38 mitogen&#x02010;activated protein kinase (p38); tumor protein p53 (p53); p70 ribosomal S6 kinase (P70S6k); and ribosomal S6 kinase 1 (RSK1) and 2 (RSK2) (each spotted in duplicate). The pairs of dots in the upper corner on the left side are positive controls. (B) Distribution of antibodies for each of the 17 MAPK phosphorylated proteins on the membrane supplied by the array.</p><p>
<bold>TABLE S1:</bold> IC<sub>50</sub> values (&#x003bc;M) of CBN tested at three different time points (6, 12, and 24&#x02009;h).</p><p>
<bold>TABLE S2:</bold> Primers used for RT&#x02010;qPCR analyses. All the primers for the ECS and housekeeping genes were designed with Primer3 and ordered from Integrated DNA Technologies (IDT; Coralville, IA, USA).</p><p>
<bold>TABLE S3:</bold> Primary antibodies used for western blotting analyses. All the primary antibodies used for ECS and for the housekeeping protein (&#x003b2;&#x02010;Actin) are indicated.</p></caption><media xlink:href="BIOF-51-0-s001.docx"/></supplementary-material></sec></body><back><ref-list id="biof2122-bibl-0001" content-type="cited-references"><title>REFERENCES</title><ref id="biof2122-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="biof2122-cit-0001">
<string-name>
<surname>Hanu&#x00161;</surname>
<given-names>LO</given-names>
</string-name>, <string-name>
<surname>Meyer</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Mu&#x000f1;oz</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Taglialatela&#x02010;Scafati</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Appendino</surname>
<given-names>G</given-names>
</string-name>. <article-title>Phytocannabinoids: a unified critical inventory</article-title>. <source>Nat Prod Rep</source>. <year>2016</year>;<volume>33</volume>:<fpage>1357</fpage>&#x02013;<lpage>1392</lpage>.<pub-id pub-id-type="pmid">27722705</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="biof2122-cit-0002">
<string-name>
<surname>Procaccia</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Lewitus</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Lipson Feder</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Shapira</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Berman</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Meiri</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>Cannabis for medical use: versatile plant rather than a single drug</article-title>. <source>Front Pharmacol</source>. <year>2022</year>;<volume>13</volume>:<elocation-id>894960</elocation-id>.<pub-id pub-id-type="pmid">35548332</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="biof2122-cit-0003">
<string-name>
<surname>Pisanti</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Bifulco</surname>
<given-names>M</given-names>
</string-name>. <article-title>Medical <italic toggle="yes">Cannabis</italic>: a plurimillennial history of an evergreen</article-title>. <source>J Cell Physiol</source>. <year>2019</year>;<volume>234</volume>:<fpage>8342</fpage>&#x02013;<lpage>8351</lpage>.<pub-id pub-id-type="pmid">30417354</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0004"><label>4</label><mixed-citation publication-type="book" id="biof2122-cit-0004">
<string-name>
<surname>ElSohly</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Radwan</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Gul</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Chandra</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Galal</surname>
<given-names>A</given-names>
</string-name>. <part-title>Phytochemistry of <italic toggle="yes">Cannabis sativa</italic> L</part-title>. In: <person-group person-group-type="editor">
<string-name>
<surname>Kinghorn</surname>
<given-names>AD</given-names>
</string-name>
</person-group>, <person-group person-group-type="editor">
<string-name>
<surname>Falk</surname>
<given-names>H</given-names>
</string-name>
</person-group>, <person-group person-group-type="editor">
<string-name>
<surname>Gibbons</surname>
<given-names>S</given-names>
</string-name>
</person-group>, <person-group person-group-type="editor">
<string-name>
<surname>Kobayashi</surname>
<given-names>J</given-names>
</string-name>
</person-group>, editors. <source>Phytocannabinoids, progress in the chemistry of organic natural products</source>. <publisher-loc>Cham</publisher-loc>: <publisher-name>Springer International Publishing</publisher-name>; <year>2017</year>. p. <fpage>1</fpage>&#x02013;<lpage>36</lpage>.</mixed-citation></ref><ref id="biof2122-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="biof2122-cit-0005">
<string-name>
<surname>Filipiuc</surname>
<given-names>LE</given-names>
</string-name>, <string-name>
<surname>Ababei</surname>
<given-names>DC</given-names>
</string-name>, <string-name>
<surname>Alexa&#x02010;Stratulat</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Pricope</surname>
<given-names>CV</given-names>
</string-name>, <string-name>
<surname>Bild</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Stefanescu</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Major phytocannabinoids and their related compounds: should we only search for drugs that act on cannabinoid receptors?</article-title>
<source>Pharmaceutics</source>. <year>2021</year>;<volume>13</volume>:<fpage>1823</fpage>.<pub-id pub-id-type="pmid">34834237</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="biof2122-cit-0006">
<string-name>
<surname>Walsh</surname>
<given-names>KB</given-names>
</string-name>, <string-name>
<surname>McKinney</surname>
<given-names>AE</given-names>
</string-name>, <string-name>
<surname>Holmes</surname>
<given-names>AE</given-names>
</string-name>. <article-title>Minor cannabinoids: biosynthesis, molecular pharmacology and potential therapeutic uses</article-title>. <source>Front Pharmacol</source>. <year>2021</year>;<volume>12</volume>:<elocation-id>777804</elocation-id>.<pub-id pub-id-type="pmid">34916950</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="biof2122-cit-0007">
<string-name>
<surname>Maioli</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Mattoteia</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Amin</surname>
<given-names>HIM</given-names>
</string-name>, <string-name>
<surname>Minassi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Caprioglio</surname>
<given-names>D</given-names>
</string-name>. <article-title>Cannabinol: history, syntheses, and biological profile of the greatest &#x0201c;minor&#x0201d; cannabinoid</article-title>. <source>Plants</source>. <year>2022</year>;<volume>11</volume>:<fpage>2896</fpage>.<pub-id pub-id-type="pmid">36365350</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0008"><label>8</label><mixed-citation publication-type="book" id="biof2122-cit-0008">
<string-name>
<surname>Huestis</surname>
<given-names>MA</given-names>
</string-name>. <part-title>Pharmacokinetics and metabolism of the plant cannabinoids, &#x003b4; 9&#x02010;tetrahydrocannibinol, cannabidiol and cannabinol</part-title>. In: <person-group person-group-type="editor">
<string-name>
<surname>Pertwee</surname>
<given-names>RG</given-names>
</string-name>
</person-group>, editor. <source>Cannabinoids, handbook of experimental pharmacology</source>. <publisher-loc>Berlin, Heidelberg</publisher-loc>: <publisher-name>Springer</publisher-name>; <year>2005</year>. p. <fpage>657</fpage>&#x02013;<lpage>690</lpage>.</mixed-citation></ref><ref id="biof2122-bib-0009"><label>9</label><mixed-citation publication-type="book" id="biof2122-cit-0009">
<string-name>
<surname>Morales</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Hurst</surname>
<given-names>DP</given-names>
</string-name>, <string-name>
<surname>Reggio</surname>
<given-names>PH</given-names>
</string-name>. <part-title>Molecular targets of the phytocannabinoids: a complex picture</part-title>. In: <person-group person-group-type="editor">
<string-name>
<surname>Kinghorn</surname>
<given-names>AD</given-names>
</string-name>
</person-group>, <person-group person-group-type="editor">
<string-name>
<surname>Falk</surname>
<given-names>H</given-names>
</string-name>
</person-group>, <person-group person-group-type="editor">
<string-name>
<surname>Gibbons</surname>
<given-names>S</given-names>
</string-name>
</person-group>, <person-group person-group-type="editor">
<string-name>
<surname>Kobayashi</surname>
<given-names>J</given-names>
</string-name>
</person-group>, editors. <source>Phytocannabinoids, progress in the chemistry of organic natural products</source>. <publisher-loc>Cham</publisher-loc>: <publisher-name>Springer International Publishing</publisher-name>; <year>2017</year>. p. <fpage>103</fpage>&#x02013;<lpage>131</lpage>.</mixed-citation></ref><ref id="biof2122-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="biof2122-cit-0010">
<string-name>
<surname>Jan</surname>
<given-names>T&#x02010;R</given-names>
</string-name>, <string-name>
<surname>Farraj</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Harkema</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Kaminski</surname>
<given-names>NE</given-names>
</string-name>. <article-title>Attenuation of the ovalbumin&#x02010;induced allergic airway response by cannabinoid treatment in A/J mice</article-title>. <source>Toxicol Appl Pharmacol</source>. <year>2003</year>;<volume>188</volume>:<fpage>24</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="pmid">12668119</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="biof2122-cit-0011">
<string-name>
<surname>Maccarrone</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Di Marzo</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Gertsch</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Grether</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Howlett</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Hua</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Goods and bads of the endocannabinoid system as a therapeutic target: lessons learned after 30&#x02009;years</article-title>. <source>Pharmacol Rev</source>. <year>2023</year>;<volume>75</volume>:<fpage>885</fpage>&#x02013;<lpage>958</lpage>.<pub-id pub-id-type="pmid">37164640</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="biof2122-cit-0012">
<string-name>
<surname>Maccarrone</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bab</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>B&#x000ed;r&#x000f3;</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Cabral</surname>
<given-names>GA</given-names>
</string-name>, <string-name>
<surname>Dey</surname>
<given-names>SK</given-names>
</string-name>, <string-name>
<surname>Di Marzo</surname>
<given-names>V</given-names>
</string-name>, et al. <article-title>Endocannabinoid signaling at the periphery: 50&#x02009;years after THC</article-title>. <source>Trends Pharmacol Sci</source>. <year>2015</year>;<volume>36</volume>:<fpage>277</fpage>&#x02013;<lpage>296</lpage>.<pub-id pub-id-type="pmid">25796370</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="biof2122-cit-0013">
<string-name>
<surname>Bisogno</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Maccarrone</surname>
<given-names>M</given-names>
</string-name>. <article-title>Endocannabinoid signaling and its regulation by nutrients</article-title>. <source>BioFactors</source>. <year>2014</year>;<volume>40</volume>:<fpage>373</fpage>&#x02013;<lpage>380</lpage>.<pub-id pub-id-type="pmid">24753395</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="biof2122-cit-0014">
<string-name>
<surname>T&#x000f3;th</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>&#x000c1;d&#x000e1;m</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>B&#x000ed;r&#x000f3;</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ol&#x000e1;h</surname>
<given-names>A</given-names>
</string-name>. <article-title>Cannabinoid signaling in the skin: therapeutic potential of the &#x0201c;c(ut)annabinoid&#x0201d; system</article-title>. <source>Molecules</source>. <year>2019</year>;<volume>24</volume>:<fpage>918</fpage>.<pub-id pub-id-type="pmid">30845666</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="biof2122-cit-0015">
<string-name>
<surname>Del R&#x000ed;o</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Mill&#x000e1;n</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Garc&#x000ed;a</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Appendino</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>DeMesa</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Mu&#x000f1;oz</surname>
<given-names>E</given-names>
</string-name>. <article-title>The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders</article-title>. <source>Biochem Pharmacol</source>. <year>2018</year>;<volume>157</volume>:<fpage>122</fpage>&#x02013;<lpage>133</lpage>.<pub-id pub-id-type="pmid">30138623</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="biof2122-cit-0016">
<string-name>
<surname>Cadas</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>di Tomaso</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Piomelli</surname>
<given-names>D</given-names>
</string-name>. <article-title>Occurrence and biosynthesis of endogenous cannabinoid precursor, <italic toggle="yes">N</italic>&#x02010;arachidonoyl phosphatidylethanolamine, in rat brain</article-title>. <source>J Neurosci</source>. <year>1997</year>;<volume>17</volume>:<fpage>1226</fpage>&#x02013;<lpage>1242</lpage>.<pub-id pub-id-type="pmid">9006968</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="biof2122-cit-0017">
<string-name>
<surname>Devane</surname>
<given-names>WA</given-names>
</string-name>, <string-name>
<surname>Hanu&#x00161;</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Breuer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Pertwee</surname>
<given-names>RG</given-names>
</string-name>, <string-name>
<surname>Stevenson</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Griffin</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>Isolation and structure of a brain constituent that binds to the cannabinoid receptor</article-title>. <source>Science</source>. <year>1992</year>;<volume>258</volume>:<fpage>1946</fpage>&#x02013;<lpage>1949</lpage>.<pub-id pub-id-type="pmid">1470919</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="biof2122-cit-0018">
<string-name>
<surname>Di Marzo</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Fontana</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Cadas</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Schinelli</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Cimino</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Schwartz</surname>
<given-names>JC</given-names>
</string-name>, et al. <article-title>Formation and inactivation of endogenous cannabinoid anandamide in central neurons</article-title>. <source>Nature</source>. <year>1994</year>;<volume>372</volume>:<fpage>686</fpage>&#x02013;<lpage>691</lpage>.<pub-id pub-id-type="pmid">7990962</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="biof2122-cit-0019">
<string-name>
<surname>Mechoulam</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Ben&#x02010;Shabat</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hanus</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Ligumsky</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kaminski</surname>
<given-names>NE</given-names>
</string-name>, <string-name>
<surname>Schatz</surname>
<given-names>AR</given-names>
</string-name>, et al. <article-title>Identification of an endogenous 2&#x02010;monoglyceride, present in canine gut, that binds to cannabinoid receptors</article-title>. <source>Biochem Pharmacol</source>. <year>1995</year>;<volume>50</volume>:<fpage>83</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">7605349</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="biof2122-cit-0020">
<string-name>
<surname>Sugiura</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kondo</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Sukagawa</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Nakane</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Shinoda</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Itoh</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>2&#x02010;Arachidonoylgylcerol: a possible endogenous cannabinoid receptor ligand in brain</article-title>. <source>Biochem Biophys Res Commun</source>. <year>1995</year>;<volume>215</volume>:<fpage>89</fpage>&#x02013;<lpage>97</lpage>.<pub-id pub-id-type="pmid">7575630</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="biof2122-cit-0021">
<string-name>
<surname>Okamoto</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Morishita</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Tsuboi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Tonai</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ueda</surname>
<given-names>N</given-names>
</string-name>. <article-title>Molecular characterization of a phospholipase D generating anandamide and its congeners</article-title>. <source>J Biol Chem</source>. <year>2004</year>;<volume>279</volume>:<fpage>5298</fpage>&#x02013;<lpage>5305</lpage>.<pub-id pub-id-type="pmid">14634025</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="biof2122-cit-0022">
<string-name>
<surname>Hussain</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Uyama</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Tsuboi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ueda</surname>
<given-names>N</given-names>
</string-name>. <article-title>Mammalian enzymes responsible for the biosynthesis of N&#x02010;acylethanolamines</article-title>. <source>Biochim Biophys Acta (BBA)&#x02014;Mol Cell Biol Lipids</source>. <year>2017</year>;<volume>1862</volume>:<fpage>1546</fpage>&#x02013;<lpage>1561</lpage>.</mixed-citation></ref><ref id="biof2122-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="biof2122-cit-0023">
<string-name>
<surname>Cravatt</surname>
<given-names>BF</given-names>
</string-name>, <string-name>
<surname>Giang</surname>
<given-names>DK</given-names>
</string-name>, <string-name>
<surname>Mayfield</surname>
<given-names>SP</given-names>
</string-name>, <string-name>
<surname>Boger</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Lerner</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Gilula</surname>
<given-names>NB</given-names>
</string-name>, et al. <article-title>Molecular characterization of an enzyme that degrades neuromodulatory fatty&#x02010;acid amides</article-title>. <source>Nature</source>. <year>1996</year>;<volume>384</volume>:<fpage>83</fpage>&#x02013;<lpage>87</lpage>.<pub-id pub-id-type="pmid">8900284</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="biof2122-cit-0024">
<string-name>
<surname>Bisogno</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Howell</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Williams</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Minassi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Cascio</surname>
<given-names>MG</given-names>
</string-name>, et al. <article-title>Cloning of the first sn1&#x02010;DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain</article-title>. <source>J Cell Biol</source>. <year>2003</year>;<volume>163</volume>:<fpage>463</fpage>&#x02013;<lpage>468</lpage>.<pub-id pub-id-type="pmid">14610053</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="biof2122-cit-0025">
<string-name>
<surname>Baggelaar</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>van Esbroeck</surname>
<given-names>ACM</given-names>
</string-name>, <string-name>
<surname>van Rooden</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Florea</surname>
<given-names>BI</given-names>
</string-name>, <string-name>
<surname>Overkleeft</surname>
<given-names>HS</given-names>
</string-name>, <string-name>
<surname>Marsicano</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>Chemical proteomics maps brain region specific activity of endocannabinoid hydrolases</article-title>. <source>ACS Chem Biol</source>. <year>2017</year>;<volume>12</volume>:<fpage>852</fpage>&#x02013;<lpage>861</lpage>.<pub-id pub-id-type="pmid">28106377</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="biof2122-cit-0026">
<string-name>
<surname>Gao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Vasilyev</surname>
<given-names>DV</given-names>
</string-name>, <string-name>
<surname>Goncalves</surname>
<given-names>MB</given-names>
</string-name>, <string-name>
<surname>Howell</surname>
<given-names>FV</given-names>
</string-name>, <string-name>
<surname>Hobbs</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Reisenberg</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock&#x02010;out mice</article-title>. <source>J Neurosci</source>. <year>2010</year>;<volume>30</volume>:<fpage>2017</fpage>&#x02013;<lpage>2024</lpage>.<pub-id pub-id-type="pmid">20147530</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="biof2122-cit-0027">
<string-name>
<surname>Viader</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ogasawara</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Joslyn</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Sanchez&#x02010;Alavez</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Mori</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Nguyen</surname>
<given-names>W</given-names>
</string-name>, et al. <article-title>A chemical proteomic atlas of brain serine hydrolases identifies cell type&#x02010;specific pathways regulating neuroinflammation</article-title>. <source>eLife</source>. <year>2016</year>;<volume>5</volume>:<elocation-id>e12345</elocation-id>.<pub-id pub-id-type="pmid">26779719</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="biof2122-cit-0028">
<string-name>
<surname>Hsu</surname>
<given-names>K&#x02010;L</given-names>
</string-name>, <string-name>
<surname>Tsuboi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Adibekian</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Pugh</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Masuda</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Cravatt</surname>
<given-names>BF</given-names>
</string-name>, et al. <article-title>DAGL&#x003b2; inhibition perturbs a lipid network involved in macrophage inflammatory responses</article-title>. <source>Nat Chem Biol</source>. <year>2012</year>;<volume>8</volume>:<fpage>999</fpage>&#x02013;<lpage>1007</lpage>.<pub-id pub-id-type="pmid">23103940</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="biof2122-cit-0029">
<string-name>
<surname>Shin</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Buckner</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Prince</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Bullock</surname>
<given-names>TNJ</given-names>
</string-name>, <string-name>
<surname>Hsu</surname>
<given-names>K&#x02010;L</given-names>
</string-name>. <article-title>Diacylglycerol lipase&#x02010;&#x003b2; is required for TNF&#x02010;&#x003b1; response but not CD8+ T cell priming capacity of dendritic cells</article-title>. <source>Cell Chem Biol</source>. <year>2019</year>;<volume>26</volume>:<fpage>1036</fpage>&#x02013;<lpage>1041.e3</lpage>.<pub-id pub-id-type="pmid">31105063</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="biof2122-cit-0030">
<string-name>
<surname>Dinh</surname>
<given-names>TP</given-names>
</string-name>, <string-name>
<surname>Carpenter</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Leslie</surname>
<given-names>FM</given-names>
</string-name>, <string-name>
<surname>Freund</surname>
<given-names>TF</given-names>
</string-name>, <string-name>
<surname>Katona</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Sensi</surname>
<given-names>SL</given-names>
</string-name>, et al. <article-title>Brain monoglyceride lipase participating in endocannabinoid inactivation</article-title>. <source>Proc Natl Acad Sci</source>. <year>2002</year>;<volume>99</volume>:<fpage>10819</fpage>&#x02013;<lpage>10824</lpage>.<pub-id pub-id-type="pmid">12136125</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="biof2122-cit-0031">
<string-name>
<surname>B&#x000ed;r&#x000f3;</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>T&#x000f3;th</surname>
<given-names>BI</given-names>
</string-name>, <string-name>
<surname>Hask&#x000f3;</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Paus</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Pacher</surname>
<given-names>P</given-names>
</string-name>. <article-title>The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities</article-title>. <source>Trends Pharmacol Sci</source>. <year>2009</year>;<volume>30</volume>:<fpage>411</fpage>&#x02013;<lpage>420</lpage>.<pub-id pub-id-type="pmid">19608284</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="biof2122-cit-0032">
<string-name>
<surname>Pasquariello</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Oddi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Malaponti</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Maccarrone</surname>
<given-names>M</given-names>
</string-name>. <article-title>Chapter 17 regulation of gene transcription and keratinocyte differentiation by anandamide</article-title>. <source>Vitamin Hormone</source>. <year>2009</year>;<volume>81</volume>:<fpage>441</fpage>&#x02013;<lpage>467</lpage>.</mixed-citation></ref><ref id="biof2122-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="biof2122-cit-0033">
<string-name>
<surname>Pucci</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rapino</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Di Francesco</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Dainese</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>D'Addario</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Maccarrone</surname>
<given-names>M</given-names>
</string-name>. <article-title>Epigenetic control of skin differentiation genes by phytocannabinoids: epigenesis of skin genes by phytocannabinoids</article-title>. <source>Br J Pharmacol</source>. <year>2013</year>;<volume>170</volume>:<fpage>581</fpage>&#x02013;<lpage>591</lpage>.<pub-id pub-id-type="pmid">23869687</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="biof2122-cit-0034">
<string-name>
<surname>Maccarrone</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Finazzi&#x02010;Agr&#x000f3;</surname>
<given-names>A</given-names>
</string-name>. <article-title>The endocannabinoid system, anandamide and the regulation of mammalian cell apoptosis</article-title>. <source>Cell Death Diff</source>. <year>2003</year>;<volume>10</volume>:<fpage>946</fpage>&#x02013;<lpage>955</lpage>.</mixed-citation></ref><ref id="biof2122-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="biof2122-cit-0035">
<string-name>
<surname>Di Meo</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Tortolani</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Standoli</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Angelucci</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Fanti</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Leuti</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Effects of rare phytocannabinoids on the endocannabinoid system of human keratinocytes</article-title>. <source>Int J Mol Sci</source>. <year>2022</year>;<volume>23</volume>:<fpage>5430</fpage>.<pub-id pub-id-type="pmid">35628241</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="biof2122-cit-0036">
<string-name>
<surname>Tortolani</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Di Meo</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Standoli</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ciaramellano</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Kadhim</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Rapino</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Rare phytocannabinoids exert anti&#x02010;inflammatory effects on human keratinocytes via the endocannabinoid system and MAPK signaling pathway</article-title>. <source>Int J Mol Sci</source>. <year>2023</year>;<volume>24</volume>:<fpage>2721</fpage>.<pub-id pub-id-type="pmid">36769042</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="biof2122-cit-0037">
<string-name>
<surname>Pucci</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Pasquariello</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Battista</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Di Tommaso</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rapino</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Fezza</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>Endocannabinoids stimulate human melanogenesis via Type&#x02010;1 cannabinoid receptor</article-title>. <source>J Biol Chem</source>. <year>2012</year>;<volume>287</volume>:<fpage>15466</fpage>&#x02013;<lpage>15478</lpage>.<pub-id pub-id-type="pmid">22431736</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="biof2122-cit-0038">
<string-name>
<surname>T&#x000f3;th</surname>
<given-names>BI</given-names>
</string-name>, <string-name>
<surname>Dobrosi</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Dajnoki</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Czifra</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Ol&#x000e1;h</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sz&#x000f6;ll&#x00151;si</surname>
<given-names>AG</given-names>
</string-name>, et al. <article-title>Endocannabinoids modulate human epidermal keratinocyte proliferation and survival via the sequential engagement of cannabinoid receptor&#x02010;1 and transient receptor potential vanilloid&#x02010;1</article-title>. <source>J Invest Dermat</source>. <year>2011</year>;<volume>131</volume>:<fpage>1095</fpage>&#x02013;<lpage>1104</lpage>.</mixed-citation></ref><ref id="biof2122-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="biof2122-cit-0039">
<string-name>
<surname>Bari</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Battista</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Fezza</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Finazzi&#x02010;Agr&#x000f2;</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Maccarrone</surname>
<given-names>M</given-names>
</string-name>. <article-title>Lipid rafts control signaling of type&#x02010;1 cannabinoid receptors in neuronal cells</article-title>. <source>J Biol Chem</source>. <year>2005</year>;<volume>280</volume>:<fpage>12212</fpage>&#x02013;<lpage>12220</lpage>.<pub-id pub-id-type="pmid">15657045</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="biof2122-cit-0040">
<string-name>
<surname>Lyon</surname>
<given-names>E</given-names>
</string-name>. <article-title>Mutation detection using fluorescent hybridization probes and melting curve analysis</article-title>. <source>Exp Rev Mol Diag</source>. <year>2001</year>;<volume>1</volume>:<fpage>92</fpage>&#x02013;<lpage>101</lpage>.</mixed-citation></ref><ref id="biof2122-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="biof2122-cit-0041">
<string-name>
<surname>Livak</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Schmittgen</surname>
<given-names>TD</given-names>
</string-name>. <article-title>Analysis of relative gene expression data using real&#x02010;time quantitative PCR and the 2&#x02212;&#x00394;&#x00394;CT method</article-title>. <source>Methods</source>. <year>2001</year>;<volume>25</volume>:<fpage>402</fpage>&#x02013;<lpage>408</lpage>.<pub-id pub-id-type="pmid">11846609</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="biof2122-cit-0042">
<string-name>
<surname>Francavilla</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Battista</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Barbonetti</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Vassallo</surname>
<given-names>MRC</given-names>
</string-name>, <string-name>
<surname>Rapino</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Antonangelo</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Characterization of the endocannabinoid system in human spermatozoa and involvement of transient receptor potential vanilloid 1 receptor in their fertilizing ability</article-title>. <source>Endocrinology</source>. <year>2009</year>;<volume>150</volume>:<fpage>4692</fpage>&#x02013;<lpage>4700</lpage>.<pub-id pub-id-type="pmid">19608651</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="biof2122-cit-0043">
<string-name>
<surname>Rapino</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Castellucci</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lizzi</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Sabatucci</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Angelucci</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Tortolani</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>Modulation of endocannabinoid&#x02010;binding receptors in human neuroblastoma cells by tunicamycin</article-title>. <source>Molecules</source>. <year>2019</year>;<volume>24</volume>:<fpage>1432</fpage>.<pub-id pub-id-type="pmid">30979007</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="biof2122-cit-0044">
<string-name>
<surname>Petrosino</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Schiano Moriello</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Cerrato</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Fusco</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Puigdemont</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>De Petrocellis</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>The anti&#x02010;inflammatory mediator palmitoylethanolamide enhances the levels of 2&#x02010;arachidonoyl&#x02010;glycerol and potentiates its actions at TRPV1 cation channels: novel palmitoylethanolamide &#x02018;entourage effects</article-title>&#x02019;. <source>Br J Pharmacol</source>. <year>2016</year>;<volume>173</volume>:<fpage>1154</fpage>&#x02013;<lpage>1162</lpage>.<pub-id pub-id-type="pmid">25598150</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="biof2122-cit-0045">
<string-name>
<surname>Castellani</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Diamanti</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Pizzirani</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Tardia</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Maccesi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Realini</surname>
<given-names>N</given-names>
</string-name>, et al. <article-title>Synthesis and characterization of the first inhibitor of <italic toggle="yes">N</italic>&#x02010;acylphosphatidylethanolamine phospholipase D (NAPE&#x02010;PLD)</article-title>. <source>Chem Commun</source>. <year>2017</year>;<volume>53</volume>:<fpage>12814</fpage>&#x02013;<lpage>12817</lpage>.</mixed-citation></ref><ref id="biof2122-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="biof2122-cit-0046">
<string-name>
<surname>Darrow</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Olson</surname>
<given-names>MW</given-names>
</string-name>, <string-name>
<surname>Xin</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Burke</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Schalk&#x02010;Hihi</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>A novel fluorogenic substrate for the measurement of endothelial lipase activity</article-title>. <source>J Lipid Res</source>. <year>2011</year>;<volume>52</volume>:<fpage>374</fpage>&#x02013;<lpage>382</lpage>.<pub-id pub-id-type="pmid">21062953</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="biof2122-cit-0047">
<string-name>
<surname>Oddi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Bari</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Battista</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Barsacchi</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Cozzani</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Maccarrone</surname>
<given-names>M</given-names>
</string-name>. <article-title>Confocal microscopy and biochemical analysis reveal spatial and functional separation between anandamide uptake and hydrolysis in human keratinocytes</article-title>. <source>Cell Mol Life Sci</source>. <year>2005</year>;<volume>62</volume>:<fpage>386</fpage>&#x02013;<lpage>395</lpage>.<pub-id pub-id-type="pmid">15723173</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="biof2122-cit-0048">
<string-name>
<surname>Oddi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Caporali</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Dragotto</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Totaro</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Maiolati</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Scipioni</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>The endocannabinoid system is affected by cholesterol dyshomeostasis: insights from a murine model of Niemann Pick type C disease</article-title>. <source>Neurobiol Dis</source>. <year>2019</year>;<volume>130</volume>:<elocation-id>104531</elocation-id>.<pub-id pub-id-type="pmid">31302243</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="biof2122-cit-0049">
<string-name>
<surname>Moens</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Kostenko</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Sveinbj&#x000f8;rnsson</surname>
<given-names>B</given-names>
</string-name>. <article-title>The role of mitogen&#x02010;activated protein kinase&#x02010;activated protein kinases (MAPKAPKs) in inflammation</article-title>. <source>Genes</source>. <year>2013</year>;<volume>4</volume>:<fpage>101</fpage>&#x02013;<lpage>133</lpage>.<pub-id pub-id-type="pmid">24705157</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="biof2122-cit-0050">
<string-name>
<surname>Song</surname>
<given-names>W&#x02010;J</given-names>
</string-name>, <string-name>
<surname>Song</surname>
<given-names>E&#x02010;AC</given-names>
</string-name>, <string-name>
<surname>Jung</surname>
<given-names>M&#x02010;S</given-names>
</string-name>, <string-name>
<surname>Choi</surname>
<given-names>S&#x02010;H</given-names>
</string-name>, <string-name>
<surname>Baik</surname>
<given-names>H&#x02010;H</given-names>
</string-name>, <string-name>
<surname>Jin</surname>
<given-names>BK</given-names>
</string-name>, et al. <article-title>Phosphorylation and inactivation of glycogen synthase kinase 3&#x003b2; (GSK3&#x003b2;) by dual&#x02010;specificity tyrosine phosphorylation&#x02010;regulated kinase 1A (Dyrk1A)</article-title>. <source>J Biol Chem</source>. <year>2015</year>;<volume>290</volume>:<fpage>2321</fpage>&#x02013;<lpage>2333</lpage>.<pub-id pub-id-type="pmid">25477508</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="biof2122-cit-0051">
<string-name>
<surname>Gaffal</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Cron</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Glodde</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>T&#x000fc;ting</surname>
<given-names>T</given-names>
</string-name>. <article-title>Anti&#x02010;inflammatory activity of topical THC in DNFB&#x02010;mediated mouse allergic contact dermatitis independent of CB1 and CB2 receptors</article-title>. <source>Allergy</source>. <year>2013</year>;<volume>68</volume>:<fpage>994</fpage>&#x02013;<lpage>1000</lpage>.<pub-id pub-id-type="pmid">23889474</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="biof2122-cit-0052">
<string-name>
<surname>Friedman</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Momeni</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kogan</surname>
<given-names>M</given-names>
</string-name>. <article-title>Topical cannabinoids for the management of psoriasis vulgaris: report of a case and review of the literature</article-title>. <source>J Drugs Dermatol</source>. <year>2020</year>;<volume>19</volume>:<fpage>795</fpage>.<pub-id pub-id-type="pmid">32845594</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="biof2122-cit-0053">
<string-name>
<surname>Ol&#x000e1;h</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>T&#x000f3;th</surname>
<given-names>BI</given-names>
</string-name>, <string-name>
<surname>Borb&#x000ed;r&#x000f3;</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Sugawara</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Sz&#x000f6;ll&#x000f5;si</surname>
<given-names>AG</given-names>
</string-name>, <string-name>
<surname>Czifra</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes</article-title>. <source>J Clin Invest</source>. <year>2014</year>;<volume>124</volume>:<fpage>3713</fpage>&#x02013;<lpage>3724</lpage>.<pub-id pub-id-type="pmid">25061872</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="biof2122-cit-0054">
<string-name>
<surname>Colombo</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Rusconi</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Rubino</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Cattaneo</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Martegani</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Parolaro</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>Transcriptomic and proteomic analyses of mouse cerebellum reveals alterations in RasGRF1 expression following in vivo chronic treatment with delta 9&#x02010;tetrahydrocannabinol</article-title>. <source>J Mol Neurosci</source>. <year>2009</year>;<volume>37</volume>:<fpage>111</fpage>&#x02013;<lpage>122</lpage>.<pub-id pub-id-type="pmid">18584336</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="biof2122-cit-0055">
<string-name>
<surname>Bari</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Tedesco</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Battista</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Pasquariello</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Pucci</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gasperi</surname>
<given-names>V</given-names>
</string-name>, et al. <article-title>Characterization of the endocannabinoid system in mouse embryonic stem cells</article-title>. <source>Stem Cell Dev</source>. <year>2011</year>;<volume>20</volume>:<fpage>139</fpage>&#x02013;<lpage>147</lpage>.</mixed-citation></ref><ref id="biof2122-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="biof2122-cit-0056">
<string-name>
<surname>Erickson</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Luo</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Even</surname>
<given-names>Z</given-names>
</string-name>, et al. <article-title>Genetic architecture of protein expression and its regulation in the mouse brain</article-title>. <source>BMC Genom</source>. <year>2021</year>;<volume>22</volume>:<fpage>875</fpage>.</mixed-citation></ref><ref id="biof2122-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="biof2122-cit-0057">
<string-name>
<surname>Fournier</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Paulson</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Pavelka</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Mosley</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Gaudenz</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Bradford</surname>
<given-names>WD</given-names>
</string-name>, et al. <article-title>Delayed correlation of mRNA and protein expression in rapamycin&#x02010;treated cells and a role for Ggc1 in cellular sensitivity to rapamycin</article-title>. <source>Mol Cell Prot</source>. <year>2010</year>;<volume>9</volume>:<fpage>271</fpage>&#x02013;<lpage>284</lpage>.</mixed-citation></ref><ref id="biof2122-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="biof2122-cit-0058">
<string-name>
<surname>Vogel</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Silva</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Marcotte</surname>
<given-names>EM</given-names>
</string-name>. <article-title>Protein expression regulation under oxidative stress</article-title>. <source>Mol Cell Prot</source>. <year>2011</year>;<volume>10</volume>(<issue>M111</issue>):<elocation-id>009217</elocation-id>.</mixed-citation></ref><ref id="biof2122-bib-0059"><label>59</label><mixed-citation publication-type="journal" id="biof2122-cit-0059">
<string-name>
<surname>Rhee</surname>
<given-names>M&#x02010;H</given-names>
</string-name>, <string-name>
<surname>Vogel</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Barg</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Bayewitch</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Levy</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Hanu&#x00161;</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase</article-title>. <source>J Med Chem</source>. <year>1997</year>;<volume>40</volume>:<fpage>3228</fpage>&#x02013;<lpage>3233</lpage>.<pub-id pub-id-type="pmid">9379442</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0060"><label>60</label><mixed-citation publication-type="journal" id="biof2122-cit-0060">
<string-name>
<surname>De Petrocellis</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Ligresti</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Moriello</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Allar&#x000e0;</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bisogno</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Petrosino</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Effects of cannabinoids and cannabinoid&#x02010;enriched <italic toggle="yes">Cannabis</italic> extracts on TRP channels and endocannabinoid metabolic enzymes: novel pharmacology of minor plant cannabinoids</article-title>. <source>Br J Pharmacol</source>. <year>2011</year>;<volume>163</volume>:<fpage>1479</fpage>&#x02013;<lpage>1494</lpage>.<pub-id pub-id-type="pmid">21175579</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0061"><label>61</label><mixed-citation publication-type="journal" id="biof2122-cit-0061">
<string-name>
<surname>Henshaw</surname>
<given-names>FR</given-names>
</string-name>, <string-name>
<surname>Dewsbury</surname>
<given-names>LS</given-names>
</string-name>, <string-name>
<surname>Lim</surname>
<given-names>CK</given-names>
</string-name>, <string-name>
<surname>Steiner</surname>
<given-names>GZ</given-names>
</string-name>. <article-title>The effects of cannabinoids on pro&#x02010; and anti&#x02010;inflammatory cytokines: a systematic review of <italic toggle="yes">in vivo</italic> studies</article-title>. <source>Cannabis Cannabinoid Res</source>. <year>2021</year>;<volume>6</volume>:<fpage>177</fpage>&#x02013;<lpage>195</lpage>.<pub-id pub-id-type="pmid">33998900</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0062"><label>62</label><mixed-citation publication-type="journal" id="biof2122-cit-0062">
<string-name>
<surname>Nagarkatti</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Pandey</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Rieder</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Hegde</surname>
<given-names>VL</given-names>
</string-name>, <string-name>
<surname>Nagarkatti</surname>
<given-names>M</given-names>
</string-name>. <article-title>Cannabinoids as novel anti&#x02010;inflammatory drugs</article-title>. <source>Fut Med Chem</source>. <year>2009</year>;<volume>1</volume>:<fpage>1333</fpage>&#x02013;<lpage>1349</lpage>.</mixed-citation></ref><ref id="biof2122-bib-0063"><label>63</label><mixed-citation publication-type="journal" id="biof2122-cit-0063">
<string-name>
<surname>Noske</surname>
<given-names>K</given-names>
</string-name>. <article-title>Secreted immunoregulatory proteins in the skin</article-title>. <source>J Dermatol Sci</source>. <year>2018</year>;<volume>89</volume>:<fpage>3</fpage>&#x02013;<lpage>10</lpage>.<pub-id pub-id-type="pmid">29111181</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0064"><label>64</label><mixed-citation publication-type="journal" id="biof2122-cit-0064">
<string-name>
<surname>Bernard</surname>
<given-names>F&#x02010;X</given-names>
</string-name>, <string-name>
<surname>Morel</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Camus</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Pedretti</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Barrault</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Garnier</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Keratinocytes under fire of proinflammatory cytokines: bona fide innate immune cells involved in the physiopathology of chronic atopic dermatitis and psoriasis</article-title>. <source>J Allergy</source>. <year>2012</year>;<volume>2012</volume>:<fpage>1</fpage>&#x02013;<lpage>10</lpage>.</mixed-citation></ref><ref id="biof2122-bib-0065"><label>65</label><mixed-citation publication-type="journal" id="biof2122-cit-0065">
<string-name>
<surname>Zheng</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Danilenko</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Valdez</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Kasman</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Eastham&#x02010;Anderson</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Interleukin&#x02010;22, a TH17 cytokine, mediates IL&#x02010;23&#x02010;induced dermal inflammation and acanthosis</article-title>. <source>Nature</source>. <year>2007</year>;<volume>445</volume>:<fpage>648</fpage>&#x02013;<lpage>651</lpage>.<pub-id pub-id-type="pmid">17187052</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0066"><label>66</label><mixed-citation publication-type="journal" id="biof2122-cit-0066">
<string-name>
<surname>Kulig</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Musiol</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Freiberger</surname>
<given-names>SN</given-names>
</string-name>, <string-name>
<surname>Schreiner</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Gy&#x000fc;lveszi</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Russo</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>IL&#x02010;12 protects from psoriasiform skin inflammation</article-title>. <source>Nat Commun</source>. <year>2016</year>;<volume>7</volume>:<fpage>13466</fpage>.<pub-id pub-id-type="pmid">27892456</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0067"><label>67</label><mixed-citation publication-type="journal" id="biof2122-cit-0067">
<string-name>
<surname>Turchin</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Bourcier</surname>
<given-names>M</given-names>
</string-name>. <article-title>The role of interleukins in the pathogenesis of dermatological immune&#x02010;mediated diseases</article-title>. <source>Adv Ther</source>. <year>2022</year>;<volume>39</volume>:<fpage>4474</fpage>&#x02013;<lpage>4508</lpage>.<pub-id pub-id-type="pmid">35997892</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0068"><label>68</label><mixed-citation publication-type="journal" id="biof2122-cit-0068">
<string-name>
<surname>Leung</surname>
<given-names>DYM</given-names>
</string-name>, <string-name>
<surname>Boguniewicz</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Howell</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Nomura</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Hamid</surname>
<given-names>QA</given-names>
</string-name>. <article-title>New insights into atopic dermatitis</article-title>. <source>J Clin Invest</source>. <year>2004</year>;<volume>113</volume>:<fpage>651</fpage>&#x02013;<lpage>657</lpage>.<pub-id pub-id-type="pmid">14991059</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0069"><label>69</label><mixed-citation publication-type="journal" id="biof2122-cit-0069">
<string-name>
<surname>Trinchieri</surname>
<given-names>G</given-names>
</string-name>. <article-title>Interleukin&#x02010;12 and the regulation of innate resistance and adaptive immunity</article-title>. <source>Nat Rev Immunol</source>. <year>2003</year>;<volume>3</volume>:<fpage>133</fpage>&#x02013;<lpage>146</lpage>.<pub-id pub-id-type="pmid">12563297</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0070"><label>70</label><mixed-citation publication-type="journal" id="biof2122-cit-0070">
<string-name>
<surname>Borgia</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Custurone</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Li Pomi</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Cordiano</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Alessandrello</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Gangemi</surname>
<given-names>S</given-names>
</string-name>. <article-title>IL&#x02010;31: state of the art for an inflammation&#x02010;oriented interleukin</article-title>. <source>Int J Mol Sci</source>. <year>2022</year>;<volume>23</volume>:<fpage>6507</fpage>.<pub-id pub-id-type="pmid">35742951</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0071"><label>71</label><mixed-citation publication-type="journal" id="biof2122-cit-0071">
<string-name>
<surname>Jiang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Tsoi</surname>
<given-names>LC</given-names>
</string-name>, <string-name>
<surname>Billi</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Ward</surname>
<given-names>NL</given-names>
</string-name>, <string-name>
<surname>Harms</surname>
<given-names>PW</given-names>
</string-name>, <string-name>
<surname>Zeng</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Cytokinocytes: the diverse contribution of keratinocytes to immune responses in skin</article-title>. <source>JCI Insight</source>. <year>2020</year>;<volume>5</volume>:<elocation-id>e142067</elocation-id>.<pub-id pub-id-type="pmid">33055429</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0072"><label>72</label><mixed-citation publication-type="journal" id="biof2122-cit-0072">
<string-name>
<surname>Sonkoly</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Muller</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lauerma</surname>
<given-names>AI</given-names>
</string-name>, <string-name>
<surname>Pivarcsi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Soto</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kemeny</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>IL&#x02010;31: a new link between T cells and pruritus in atopic skin inflammation</article-title>. <source>J Allergy Clin Immunol</source>. <year>2006</year>;<volume>117</volume>:<fpage>411</fpage>&#x02013;<lpage>417</lpage>.<pub-id pub-id-type="pmid">16461142</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0073"><label>73</label><mixed-citation publication-type="journal" id="biof2122-cit-0073">
<string-name>
<surname>Szegedi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kremer</surname>
<given-names>AE</given-names>
</string-name>, <string-name>
<surname>Kezic</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Teunissen</surname>
<given-names>MBM</given-names>
</string-name>, <string-name>
<surname>Bos</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Luiten</surname>
<given-names>RM</given-names>
</string-name>, et al. <article-title>Increased frequencies of IL&#x02010;31&#x02010;producing T cells are found in chronic atopic dermatitis skin</article-title>. <source>Exp Dermat</source>. <year>2012</year>;<volume>21</volume>:<fpage>431</fpage>&#x02013;<lpage>436</lpage>.</mixed-citation></ref><ref id="biof2122-bib-0074"><label>74</label><mixed-citation publication-type="journal" id="biof2122-cit-0074">
<string-name>
<surname>Nobbe</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Dziunycz</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>M&#x000fc;hleisen</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Bilsborough</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Dillon</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>French</surname>
<given-names>LE</given-names>
</string-name>, et al. <article-title>IL&#x02010;31 expression by inflammatory cells is preferentially elevated in atopic dermatitis</article-title>. <source>Acta Derm Venereol</source>. <year>2012</year>;<volume>92</volume>:<fpage>24</fpage>&#x02013;<lpage>28</lpage>.<pub-id pub-id-type="pmid">22041865</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0075"><label>75</label><mixed-citation publication-type="journal" id="biof2122-cit-0075">
<string-name>
<surname>Dillon</surname>
<given-names>SR</given-names>
</string-name>, <string-name>
<surname>Sprecher</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Hammond</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bilsborough</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Rosenfeld&#x02010;Franklin</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Presnell</surname>
<given-names>SR</given-names>
</string-name>, et al. <article-title>Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice</article-title>. <source>Nat Immunol</source>. <year>2004</year>;<volume>5</volume>:<fpage>752</fpage>&#x02013;<lpage>760</lpage>.<pub-id pub-id-type="pmid">15184896</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0076"><label>76</label><mixed-citation publication-type="journal" id="biof2122-cit-0076">
<string-name>
<surname>Cornelissen</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Marquardt</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Czaja</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Wenzel</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Frank</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>L&#x000fc;scher&#x02010;Firzlaff</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>IL&#x02010;31 regulates differentiation and filaggrin expression in human organotypic skin models</article-title>. <source>J Allergy Clin Immunol</source>. <year>2012</year>;<volume>129</volume>:<fpage>426</fpage>&#x02013;<lpage>433.e8</lpage>.<pub-id pub-id-type="pmid">22177328</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0077"><label>77</label><mixed-citation publication-type="journal" id="biof2122-cit-0077">
<string-name>
<surname>van Drongelen</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Haisma</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Out&#x02010;Luiting</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Nibbering</surname>
<given-names>PH</given-names>
</string-name>, <string-name>
<surname>El Ghalbzouri</surname>
<given-names>A</given-names>
</string-name>. <article-title>Reduced filaggrin expression is accompanied by increased <italic toggle="yes">Staphylococcus aureus</italic> colonization of epidermal skin models</article-title>. <source>Clin Exp Allergy</source>. <year>2014</year>;<volume>44</volume>:<fpage>1515</fpage>&#x02013;<lpage>1524</lpage>.<pub-id pub-id-type="pmid">25352374</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0078"><label>78</label><mixed-citation publication-type="journal" id="biof2122-cit-0078">
<string-name>
<surname>H&#x000e4;nel</surname>
<given-names>KH</given-names>
</string-name>, <string-name>
<surname>Pfaff</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Cornelissen</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Amann</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Marquardt</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Czaja</surname>
<given-names>K</given-names>
</string-name>. <article-title>Control of the physical and antimicrobial skin barrier by an IL&#x02010;31&#x02013;IL&#x02010;1 signaling network</article-title>. <source>J Immunol</source>. <year>2016</year>;<volume>196</volume>:<fpage>3233</fpage>&#x02013;<lpage>3244</lpage>.<pub-id pub-id-type="pmid">26944931</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0079"><label>79</label><mixed-citation publication-type="journal" id="biof2122-cit-0079">
<string-name>
<surname>Gu</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Singh</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Niyogi</surname>
<given-names>RG</given-names>
</string-name>, <string-name>
<surname>Lamont</surname>
<given-names>GJ</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Lamont</surname>
<given-names>RJ</given-names>
</string-name>, et al. <article-title>Marijuana&#x02010;derived cannabinoids trigger a CB2/PI3K axis of suppression of the innate response to oral pathogens</article-title>. <source>Front Immunol</source>. <year>2019</year>;<volume>10</volume>:<fpage>2288</fpage>.<pub-id pub-id-type="pmid">31681262</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0080"><label>80</label><mixed-citation publication-type="journal" id="biof2122-cit-0080">
<string-name>
<surname>Gojani</surname>
<given-names>EG</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>D&#x02010;P</given-names>
</string-name>, <string-name>
<surname>Kovalchuk</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Kovalchuk</surname>
<given-names>I</given-names>
</string-name>. <article-title>Anti&#x02010;inflammatory effects of minor cannabinoids CBC, THCV, and CBN in human macrophages</article-title>. <source>Molecules (Basel, Switzerland)</source>. <year>2023</year>;<volume>28</volume>:<fpage>6487</fpage>.<pub-id pub-id-type="pmid">37764262</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0081"><label>81</label><mixed-citation publication-type="journal" id="biof2122-cit-0081">
<string-name>
<surname>Anil</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Peeri</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Koltai</surname>
<given-names>H</given-names>
</string-name>. <article-title>Medical cannabis activity against inflammation: active compounds and modes of action</article-title>. <source>Front Pharmacol</source>. <year>2022</year>;<volume>13</volume>:<elocation-id>908198</elocation-id>.<pub-id pub-id-type="pmid">35614947</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0082"><label>82</label><mixed-citation publication-type="journal" id="biof2122-cit-0082">
<string-name>
<surname>Chiurchi&#x000f9;</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Rapino</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Talamonti</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Leuti</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lanuti</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gueniche</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Anandamide suppresses proinflammatory T cell responses in vitro through type&#x02010;1 cannabinoid receptor&#x02013;mediated mTOR inhibition in human keratinocytes</article-title>. <source>J Immunol</source>. <year>2016</year>;<volume>197</volume>:<fpage>3545</fpage>&#x02013;<lpage>3553</lpage>.<pub-id pub-id-type="pmid">27694494</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0083"><label>83</label><mixed-citation publication-type="journal" id="biof2122-cit-0083">
<string-name>
<surname>Nattkemper</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Tey</surname>
<given-names>HL</given-names>
</string-name>, <string-name>
<surname>Valdes&#x02010;Rodriguez</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Mollanazar</surname>
<given-names>NK</given-names>
</string-name>, <string-name>
<surname>Albornoz</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>The genetics of chronic itch: gene expression in the skin of patients with atopic dermatitis and psoriasis with severe itch</article-title>. <source>J Invest Dermatol</source>. <year>2018</year>;<volume>138</volume>:<fpage>1311</fpage>&#x02013;<lpage>1317</lpage>.<pub-id pub-id-type="pmid">29317264</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0084"><label>84</label><mixed-citation publication-type="journal" id="biof2122-cit-0084">
<string-name>
<surname>Zhou</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Follansbee</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Han</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Domocos</surname>
<given-names>DT</given-names>
</string-name>, et al. <article-title>TRPV1 mediates inflammation and hyperplasia in imiquimod (IMQ)&#x02010;induced psoriasiform dermatitis (PsD) in mice</article-title>. <source>J Dermatol Sci</source>. <year>2018</year>;<volume>92</volume>:<fpage>264</fpage>&#x02013;<lpage>271</lpage>.<pub-id pub-id-type="pmid">30527377</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0085"><label>85</label><mixed-citation publication-type="journal" id="biof2122-cit-0085">
<string-name>
<surname>Yoo</surname>
<given-names>EH</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>JH</given-names>
</string-name>. <article-title>Cannabinoids and their receptors in skin diseases</article-title>. <source>Int J Mol Sci</source>. <year>2023</year>;<volume>24</volume>:<fpage>16523</fpage>.<pub-id pub-id-type="pmid">38003712</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0086"><label>86</label><mixed-citation publication-type="journal" id="biof2122-cit-0086">
<string-name>
<surname>Petrosino</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Cristino</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Karsak</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gaffal</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Ueda</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>T&#x000fc;ting</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Protective role of palmitoylethanolamide in contact allergic dermatitis: palmitoylethanolamide effects in keratinocytes</article-title>. <source>Allergy</source>. <year>2009</year>;<volume>65</volume>:<fpage>698</fpage>&#x02013;<lpage>711</lpage>.<pub-id pub-id-type="pmid">19909294</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0087"><label>87</label><mixed-citation publication-type="journal" id="biof2122-cit-0087">
<string-name>
<surname>Bisogno</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Hanu&#x00161;</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>De Petrocellis</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Tchilibon</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ponde</surname>
<given-names>DE</given-names>
</string-name>, <string-name>
<surname>Brandi</surname>
<given-names>I</given-names>
</string-name>, et al. <article-title>Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide: cannabidiol, VR1 receptors and anandamide inactivation</article-title>. <source>Br J Pharmacol</source>. <year>2001</year>;<volume>134</volume>:<fpage>845</fpage>&#x02013;<lpage>852</lpage>.<pub-id pub-id-type="pmid">11606325</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0088"><label>88</label><mixed-citation publication-type="journal" id="biof2122-cit-0088">
<string-name>
<surname>Iannotti</surname>
<given-names>FA</given-names>
</string-name>, <string-name>
<surname>Hill</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Leo</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Alhusaini</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Soubrane</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Mazzarella</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability</article-title>. <source>ACS Chem Neurosci</source>. <year>2014</year>;<volume>5</volume>:<fpage>1131</fpage>&#x02013;<lpage>1141</lpage>.<pub-id pub-id-type="pmid">25029033</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0089"><label>89</label><mixed-citation publication-type="journal" id="biof2122-cit-0089">
<string-name>
<surname>Gibbs</surname>
<given-names>BF</given-names>
</string-name>, <string-name>
<surname>Patsinakidis</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Raap</surname>
<given-names>U</given-names>
</string-name>. <article-title>Role of the pruritic cytokine IL&#x02010;31 in autoimmune skin diseases</article-title>. <source>Front Immunol</source>. <year>2019</year>;<volume>10</volume>:<fpage>1383</fpage>.<pub-id pub-id-type="pmid">31281316</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0090"><label>90</label><mixed-citation publication-type="journal" id="biof2122-cit-0090">
<string-name>
<surname>Grimstad</surname>
<given-names>&#x000d8;</given-names>
</string-name>, <string-name>
<surname>Sawanobori</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Vestergaard</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Bilsborough</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Olsen</surname>
<given-names>UB</given-names>
</string-name>, <string-name>
<surname>Gr&#x000f8;nh&#x000f8;j&#x02010;Larsen</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Anti&#x02010;interleukin&#x02010;31&#x02010;antibodies ameliorate scratching behaviour in NC/Nga mice: a model of atopic dermatitis</article-title>. <source>Exp Dermatol</source>. <year>2009</year>;<volume>18</volume>:<fpage>35</fpage>&#x02013;<lpage>43</lpage>.<pub-id pub-id-type="pmid">19054054</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0091"><label>91</label><mixed-citation publication-type="journal" id="biof2122-cit-0091">
<string-name>
<surname>Altrichter</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hawro</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>H&#x000e4;nel</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Czaja</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>L&#x000fc;scher</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Maurer</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Successful omalizumab treatment in chronic spontaneous urticaria is associated with lowering of serum <sc>il</sc>&#x02010;31 levels</article-title>. <source>J Eur Acad Dermatol Venereol</source>. <year>2016</year>;<volume>30</volume>:<fpage>454</fpage>&#x02013;<lpage>455</lpage>.<pub-id pub-id-type="pmid">25371135</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0092"><label>92</label><mixed-citation publication-type="journal" id="biof2122-cit-0092">
<string-name>
<surname>Taniguchi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Karin</surname>
<given-names>M</given-names>
</string-name>. <article-title>NF&#x02010;&#x003ba;B, inflammation, immunity and cancer: coming of age</article-title>. <source>Nat Rev Immunol</source>. <year>2018</year>;<volume>18</volume>:<fpage>309</fpage>&#x02013;<lpage>324</lpage>.<pub-id pub-id-type="pmid">29379212</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0093"><label>93</label><mixed-citation publication-type="journal" id="biof2122-cit-0093">
<string-name>
<surname>Fitzgerald</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Kagan</surname>
<given-names>JC</given-names>
</string-name>. <article-title>Toll&#x02010;like receptors and the control of immunity</article-title>. <source>Cell</source>. <year>2020</year>;<volume>180</volume>:<fpage>1044</fpage>&#x02013;<lpage>1066</lpage>.<pub-id pub-id-type="pmid">32164908</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0094"><label>94</label><mixed-citation publication-type="journal" id="biof2122-cit-0094">
<string-name>
<surname>Martin</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rehani</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Jope</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Michalek</surname>
<given-names>SM</given-names>
</string-name>. <article-title>Toll&#x02010;like receptor&#x02010;mediated cytokine production is differentially regulated by glycogen synthase kinase 3</article-title>. <source>Nat Immunol</source>. <year>2005</year>;<volume>6</volume>:<fpage>777</fpage>&#x02013;<lpage>784</lpage>.<pub-id pub-id-type="pmid">16007092</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0095"><label>95</label><mixed-citation publication-type="journal" id="biof2122-cit-0095">
<string-name>
<surname>Park</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Park&#x02010;Min</surname>
<given-names>K&#x02010;H</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Ivashkiv</surname>
<given-names>LB</given-names>
</string-name>. <article-title>Tumor necrosis factor induces GSK3 kinase&#x02010;mediated cross&#x02010;tolerance to endotoxin in macrophages</article-title>. <source>Nat Immunol</source>. <year>2011</year>;<volume>12</volume>:<fpage>607</fpage>&#x02013;<lpage>615</lpage>.<pub-id pub-id-type="pmid">21602809</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0096"><label>96</label><mixed-citation publication-type="journal" id="biof2122-cit-0096">
<string-name>
<surname>Vall&#x000e9;e</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lecarpentier</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Guillevin</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Vall&#x000e9;e</surname>
<given-names>J&#x02010;N</given-names>
</string-name>. <article-title>Effects of cannabidiol interactions with Wnt/beta&#x02010;catenin pathway and PPAR&#x00026;gamma; on oxidative stress and neuroinflammation in Alzheimer's disease</article-title>. <source>Acta Biochim Biophys Sin</source>. <year>2017</year>;<volume>49</volume>:<fpage>853</fpage>&#x02013;<lpage>866</lpage>.<pub-id pub-id-type="pmid">28981597</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0097"><label>97</label><mixed-citation publication-type="journal" id="biof2122-cit-0097">
<string-name>
<surname>Wilkinson</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Williamson</surname>
<given-names>EM</given-names>
</string-name>. <article-title>Cannabinoids inhibit human keratinocyte proliferation through a non&#x02010;CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis</article-title>. <source>J Dermatol Sci</source>. <year>2007</year>;<volume>45</volume>:<fpage>87</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">17157480</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0098"><label>98</label><mixed-citation publication-type="journal" id="biof2122-cit-0098">
<string-name>
<surname>Gawe&#x00142;&#x02010;B&#x00119;ben</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Czech</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Luca</surname>
<given-names>SV</given-names>
</string-name>. <article-title>Cannabidiol and minor phytocannabinoids: a preliminary study to assess their anti&#x02010;melanoma, anti&#x02010;melanogenic, and anti&#x02010;tyrosinase properties</article-title>. <source>Pharmaceuticals</source>. <year>2023</year>;<volume>16</volume>:<fpage>648</fpage>.<pub-id pub-id-type="pmid">37242431</pub-id>
</mixed-citation></ref><ref id="biof2122-bib-0099"><label>99</label><mixed-citation publication-type="miscellaneous" id="biof2122-cit-0099">
<article-title>INM&#x02010;755 Cannabinol (CBN) Cream</article-title>.</mixed-citation></ref><ref id="biof2122-bib-0100"><label>100</label><mixed-citation publication-type="journal" id="biof2122-cit-0100">
<string-name>
<surname>Somvanshi</surname>
<given-names>RK</given-names>
</string-name>, <string-name>
<surname>Zou</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kadhim</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Padania</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hsu</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Kumar</surname>
<given-names>U</given-names>
</string-name>, et al. <article-title>Cannabinol modulates neuroprotection and intraocular pressure: a potential multi&#x02010;target therapeutic intervention for glaucoma</article-title>. <source>Biochim Biophys Acta (BBA)&#x02014;Mol Basis Dis</source>. <year>2022</year>;<volume>1868</volume>:<fpage>166325</fpage>.</mixed-citation></ref></ref-list></back></article>